Anthelmintic compounds containing an azaindole structure

Abstract

The present invention relates to novel anthelmintic compounds. These compounds can be used, for example, for treating classes of helminthiases caused by helminths such as Dirofilaria, in particular Dirofilaria immitis.

Description

[0001] The present invention relates to novel anthelmintic compounds. These compounds can be used, for example, for treating helminthiases caused by helminths such as Dirofilaria, in particular Dirofilaria immitis. Background Art

[0002] A number of serious animal diseases are caused by helminths, which can be classified into the following categories: a) cestodes, such as Anoplocephala spp.; Dipylidium spp.; Diphyllobothrium spp.; Echinococcus spp.; Moniezia spp.; Taenia spp.; b) trematodes, such as Dicrocoelium spp.; Fasciola spp.; Paramphistomum spp.; Schistosoma spp.; or c) nematodes, such as Acanthocheilonema spp.; Ancylostoma spp.; Anecator spp.; Ascaridia spp.; Ascaris spp.; Brugia spp.; Bunostomum spp.; Capillaria spp.; Chabertia spp.; Cooperia spp.; Cyathostomum spp.; Cylicocyclus spp.; Cylicodontophorus spp.; Cylicostephanus spp.; Dictyocaulus spp.; Dracunculus spp.; Enterobius spp.; Filaroides spp.; Habronema spp.; Haemonchus spp.; Heterakis spp.; Hyostrongylus spp.; Muellerius spp.; Necator spp.; Nematodirus spp.; Onchocerca spp.; Loa loa; Ostertagia spp.; Oxyuris spp.; Parascaris spp.; Stephanurus spp.; Strongylus spp.; Syngamus spp.; Toxocara spp.; Strongyloides stercoralis; Trichuris spp.; Trichostrongylus spp.; Triodontophorus spp.; Uncinaria spp.; and / or Wuchereria spp.

[0003] The helminthiases caused by the above-mentioned helminths are also known as helminth infections. These helminths usually live in the gastrointestinal tract of the host, but they may also burrow into other organs, where they cause physiological damage. For example, Ascaridia spp. are reported to cause partial or even complete gastrointestinal obstruction in the small intestine of affected animals, especially feathered animals such as birds. In addition, another helminth, Haemonchus spp., is known to affect animals such as sheep and goats, and this infestation usually causes attachment to the gastric mucosa to suck blood from the host. Therefore, the affected animals show anemia and shortness of breath. Furthermore, Nematodirus spp. are known to form nodules in the intestines of the host they infect, which may lead to dysentery.

[0004] In addition, heartworm disease, also known as cardiovascular filariasis, is a serious and mostly fatal disease that can affect the internal organs such as the lungs and heart of pets and certain other mammals. This disease is caused by the parasitic nematode Dirofilaria immitis, which, in the adult state, can reach a length of about 30 cm and a thickness of about 1 mm. These nematodes live in the heart, lungs, and associated blood vessels, causing severe lung disease, heart failure, and damage to other internal organs such as the liver and kidneys. Therefore, heartworm infection may cause complications in the host, usually ultimately leading to the death of the host.

[0005] It is known that heartworm disease affects pets, especially dogs which are considered to be the definitive host. However, cats, ferrets, wolves, coyotes, jackals, foxes, bears, sea lions and, in rare cases, even humans (zoonosis) can also be affected by heartworms.

[0006] Heartworms must go through different stages before becoming adult worms in an infected host animal. Mosquitoes play a crucial role in the life cycle of heartworms as they are required as intermediate hosts. Adult female heartworms living in an infected host give birth to larvae called microfilariae which can circulate in the blood for up to two years and are ingested by blood-sucking mosquitoes. When a mosquito bites and takes blood from such an infected host, it takes away the said microfilariae which start to develop inside the mosquito, such that the first and second larval stages (L 1 ) and (L 2 ) of heartworm development occur inside the mosquito. Once the said larvae mature to the third larval stage (L 3 ), i.e., the infective larval stage, the mosquito locates and bites a host and these infective larvae are deposited on the skin surface of the host and enter the new host through the mosquito bite, being under the skin at the bite site. After further growth for a short period of about 2 weeks, they develop to the fourth larval stage (L 4 ) and migrate to the chest and abdominal muscles. 45 to 60 days after infection, the larvae become immature adult worms (fifth larval stage; L 5 ), and between 75 and 120 days after infection (mosquito bite), these immature heartworms enter the blood and are carried to the heart and lung system where, over the next approximately three months, their body size increases significantly. Seven months after infection (mosquito bite), the adult worms mate and the female starts to produce the said microfilariae. Mature heartworms can survive for about 7 years in dogs and about 3 years in cats. Due to the long lifespan of these worms, each mosquito season leads to an increase in the number of heartworms in the infected pet's body.

[0007] Due to the widespread use of anthelmintic compounds, highly drug-resistant worm populations have been reported to have emerged. The emergence of such drug-resistance against known anthelmintics is thought to pose an increasing problem for the successful treatment of the above-mentioned disease.

[0008] WO 2017 / 178416 discloses a compound which is considered to be an anthelmintic, namely a pyrazolopyrimidine derivative having the following structure

[0009]

[0010] wherein the residues R 1 , R 2 , R 3 , R 4, Q, X, and Y are defined accordingly.

[0011] These molecules are thought to be modulators of the nematode calcium-activated potassium channel slo-1, where slo-1 is thought to be the worm ortholog of the human KCa1.1 channel (potassium calcium-activated channel subfamily M alpha-1), encoded by the KCNMA1 gene (KCa1.1 and KCNMA1 are often used interchangeably). Slo-1 exhibits calcium-activated potassium channel activity and voltage-gated potassium channel activity. The Slo-1 channel plays an important role in neuromuscular washout and secretory cells, etc. Thus, slo-1 modulators have been reported to be involved in several processes, including behavioral responses to ethanol, locomotion, and pharyngeal pumping. More specifically, it disrupts neuromuscular transmission, leading to flaccid paralysis, and also affects feeding and egg-laying. In addition, it slows down the development of the corresponding worm larvae and adults.

[0012] However, especially in view of the emergence of resistance to known anthelmintic compounds, there is still an urgent need for new active pharmaceutical ingredients that can address worm infections.

[0013] Accordingly, an object of the present invention is to overcome one or more deficiencies of the prior art.

[0014] One aim is to provide new anthelmintic compounds which can be used to address infections in mammals, particularly pets such as cats and dogs, especially dogs. In particular, one aim is to provide new anthelmintic compounds which can be used to address infections in mammals caused by parasites such as Ostertagia ostertagi, Cooperia oncophora, Cooperia punctata, Trichostrongylus axei, Haemonchus placei, Haemonchus contortus, Nematodirus helvetianus, Nematodirus spathiger, Trichostrongylus colubriformis, Trichostrongylus circumcincta, Oesophagostomum venulosum, Chabertia ovina, Dictyocaulus viviparous, Dictyocaulus filaria, Dirofilaria immitis, Dirofilaria repens; b) trematodes: Fasciola hepatica, Fascioloides magna, Dicrocoelium dentriticum, Paramphistomum cervi, c) cestodes: Monezia expansai, in particular Ascaridia galli, Haemonchus contortus, Oesophagostomum dentatum and Acanthocheilonema viteae, and infections by Dirofilaria immitis, in particular by Dirofilaria immitis (heartworm).

[0015] Another object is to provide novel anthelmintic compounds that can be used to treat mammalian infections, where these compounds are compatible with standard antiparasitic treatments for pets, particularly cats and dogs, especially dogs. In particular, an object is to provide novel anthelmintic compounds that can be used to address infections in pets such as cats and dogs and can be administered orally or topically.

[0016] More specifically, an object is to provide novel anthelmintic compounds that can be used to address infections in mammals caused by parasites, particularly infections caused by Dirofilaria immitis (heartworm), without having a negative impact on the host due to unwanted side effects.

[0017] In addition, an object is that the novel anthelmintic compounds can be used in different treatment regimens, particularly monthly or longer treatment regimens. Summary of the Invention

[0018] Surprisingly, at least one object can be met by providing a compound according to formula (I):

[0019]

[0020] R 1 independently selected from

[0021] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10 aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, C 1-6- alkylthio, halogen, cyano, nitro, hydroxy, mercapto, NR 2 R 3 、COOH, C(=O)OR 4 、SR 4 、SOR 4 、SO 2 R 4 、SO 2 NR 5 R 6 and C(=O)NR 5 R 6 ,

[0022] where C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10 aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy or C 1-6-Each alkylthio group is optionally independently substituted with one or more substituents independently selected from the following

[0023] C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, C 1-6- alkylthio, halogen, cyano, nitro, hydroxy, mercapto, NR 2’ R 3’ , C(=O)OR 4’ , SR 4’ , SOR 4’ , SO 2 R 4’ , SO 2 NR 5’ R 6’ and C(=O)NR 5’ R 6’ ,

[0024] R 2 and R 3 are independently selected from

[0025] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy-C 1-6- alkyl, C 3-10- alkyl substituted with cycloalkyl, C 1-6- alkyl substituted with a 5- to 10-membered heterocyclic group, C 1-6- alkyl, C 6-10- alkyl substituted with aryl, C 1-6- alkyl and C 1-6- alkyl substituted with a 5- to 10-membered heteroaryl, or

[0026] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0027] wherein C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10-Aryl, 5- to 10-membered heteroaryl, C 1-6- -alkoxy-C 1-6- -alkyl, C 3-10- -alkyl substituted with cycloalkyl, C 1-6- -alkyl, C 1-6- -alkyl substituted with 5- to 10-membered heterocyclic group, C 6-10- -alkyl substituted with aryl, C 1-6- -alkyl or C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl, or a heterocycle formed by R 2 and the N atom to which it is attached is optionally substituted with one or more substituents independently selected from the following 3 :

[0028] C 1-6- -alkyl, C 2-6- -alkenyl, C 2-6- -alkynyl, C 3-10- -cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- -aryl, 5- to 10-membered heteroaryl, C 1-6- -alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 2” R 3” , C(=O)OR 4” , SR 4” , SOR 4 , SO 2 R 4” , SO 2 NR 5” R 6” and C(=O)NR 5” R 6” ;

[0029] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- -alkyl,

[0030] R 2’ 、R 3’ 、R 4’ 、R 5’ and R 6’ are independently selected from hydrogen and C 1-6- -alkyl,

[0031] R 2” 、R 3” 、R 4” 、R 5” and R 6” are independently selected from hydrogen and C 1-6- -alkyl,

[0032] R 7 is independently selected from

[0033] Hydrogen, C 1-6- Alkyl, C 2-6- Alkenyl, C 2-6- Alkynyl, C 3-10- Cycloalkyl, 4- to 10-membered heterocyclic group, C 6-10 Aryl, 5- to 10-membered heteroaryl, C 1-6- Alkoxy, C 1-6- Alkylthio, halogen, cyano, nitro, hydroxy, mercapto, NR 8 R 9 、COOH, C(=O)OR 10 、SR 10 、SOR 10 、SO 2 R 10 、SO 2 NR 11 R 12 and C(=O)NR 11 R 12 ,

[0034] wherein C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy or C 1-6- alkylthio is each optionally independently substituted with one or more substituents selected from the following

[0035] C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, C 1-6- alkylthio, halogen, cyano, nitro, hydroxy, mercapto, NR 8’ R 9’ 、C(=O)OR 10’ 、SR 10’ 、SOR 10’ 、SO 2 R 10’ 、SO 2 NR 11’ R 12’ and C(=O)NR 11’ R 12’ ,

[0036] R 8 and R9 Independently selected from

[0037] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy-C 1-6- alkyl, C 3-10- alkyl substituted with cycloalkyl 1-6- alkyl, Calkyl substituted with a 5- to 10-membered heterocyclic group 1-6- alkyl, Calkyl substituted with aryl 6-10- alkyl, Calkyl substituted with a 5- to 10-membered heteroaryl 1-6- alkyl, or

[0038] R 1-6- and R 8 together with the N atom to which it is attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0039] wherein C 9 alkyl, C 1-6- alkenyl, C 2-6- alkynyl, C 2-6- cycloalkyl, 5- to 10-membered heterocyclic group, C 3-10- aryl, 5- to 10-membered heteroaryl, C 6-10- alkoxy-C 1-6- alkyl, C 1-6- alkyl substituted with cycloalkyl 3-10- alkyl, C alkyl substituted with a 5- to 10-membered heterocyclic group 1-6- alkyl, C alkyl substituted with aryl 1-6 alkyl or C alkyl substituted with a 5- to 10-membered heteroaryl 6-10 alkyl or a heterocycle formed by R 1-6 1-6 8 9 each of which is optionally substituted with one or more substituents independently selected from the following

[0040] C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 8” R 9”, C(=O)OR 10” , SR 10” , SOR 10” , SO 2 R 10” , SO 2 , NR 11” R 12” and C(=O)NR 11” R 12” ;

[0041] R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[0042] R 8’ , R 9’ , R 10’ , R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[0043] R 8” , R 9” , R 10” , R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl,

[0044] R 13 is hydrogen or C 1-3 alkyl,

[0045] R 14 is hydrogen, C 1-3 alkyl, C 1-3 alkoxy, NR 14’ R 14” , where R 14’ and R 14” are independently C 1-3- alkyl, or

[0046] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, where the ring containing 5 or 6 carbon atoms is optionally substituted by one or more C 1-3 -alkyl or =O, and / or where one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O-, -S(O)-, -S(O) 2 - or -S-, or

[0047] R 13 and R 14Together with the atom to which it is attached, form an aromatic ring containing 5 or 6 carbon atoms, wherein the ring containing 5 or 6 carbon atoms is optionally substituted by one or more C 1-3- alkyl groups, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[0048] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” , where R 15’ and R 15” are independently C 1-3- alkyl,

[0049] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” , where R 16’ and R 16” are independently C 1-3- alkyl,

[0050] R 17 is independently hydrogen, C 1-3 alkyl, C 1-3 alkoxy or NR 17’ R 17” , where R 17’ and R 17” are independently C 1-3- alkyl,

[0051] R 18 is independently hydrogen, C 1-3 alkyl, C 1-3 alkoxy or NR 18’ R 18” , where R 18’ and R 18” are independently C 1-3- alkyl,

[0052] R 19 is independently selected from C 6-10- aryl and 5- to 10-membered heteroaryl,

[0053] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted by one or more substituents independently selected from the following

[0054] C 1-6- alkyl, C 2-6- alkenyl, C 3-10-Cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- Aryl, 5- to 10-membered heteroaryl, C 1-6- Alkoxy, C 1-6- Alkylthio, halogen, cyano, nitro, hydroxy, mercapto, NR 20 R 21 , C(=O)OR 22 , SR 22 , SOR 22 , SO 2 R 22 , SO 2 , NR 23 R 24 and C(=O)NR 23 R 24 ,

[0055] R 20 and R 21 are independently selected from

[0056] Hydrogen, C 1-6- Alkyl, C 3-10- Cycloalkyl, C 6-10- Aryl, 5- to 10-membered heteroaryl, C 1-6- Alkoxy-C 1-6- alkyl, C 6-10- aryl-substituted C 1- C 6- alkyl, 5- to 10-membered heteroaryl-substituted C 1-6- alkyl, or

[0057] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0058] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy or C 1-6- alkylthio or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted independently by one or more substituents selected from

[0059] C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10-Aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 20’ R 21’ 、C(=O)OR 22’ 、SR 22’ 、SOR 22’ 、SO 2 R 22’ 、SO 2 NR 23’ R 24’ and C(=O)NR 23’ R 24’

[0060] R 22 、R 23 、and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[0061] R 20’ 、R 21’ 、R 22’ 、R 23’ 、and R 24’ are independently selected from hydrogen and C 1-6- alkyl,

[0062] R 25 is independently selected from hydrogen and C 1-6- alkyl,

[0063] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs, and mixtures.

[0064] In one embodiment of the present invention and / or its embodiments, R 1 is independently selected from: hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 、C(=O)OR 4 、and C(=O)NR 5 R 6 ,

[0065] wherein C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0066] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, and NR 2’ R 3’ ,

[0067] R2 and R 3 are independently selected from

[0068] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[0069] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0070] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 2 and R 3 together with the N atom to which they are attached are each optionally substituted with one or more substituents independently selected from the following C 1-6- alkyl, C 3-10- cycloalkyl and C 1-6- alkoxy,

[0071] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl,

[0072] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl.

[0073] In one embodiment of the present invention and / or its embodiments, R 1 is independently selected from: hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen,

[0074] wherein C 1-6- alkyl or C 1-6- alkoxy are each optionally substituted with one or more substituents independently selected from the following

[0075] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[0076] wherein R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl.

[0077] In one embodiment of the present invention and / or its embodiments, R 1 is independently selected from: hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride, and chloride.

[0078] In one embodiment of the present invention and / or its embodiments, R 7 is independently selected from: hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 、C(=O)OR 10 、SR 10 、SOR 10 、SO 2 R 10 and C(=O)NR 11 R 12 ,

[0079] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0080] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ 、C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[0081] R 8 and R 9 are independently selected from

[0082] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group and 5- to 10-membered heteroaryl or

[0083] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O;

[0084] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, and 5- to 10-membered heteroaryl, or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is each optionally substituted by one or more substituents independently selected from the following

[0085] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” 、C(=O)-OR 10” and C(=O)NR 11” R 12” ;

[0086] R 10 、R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[0087] R 8’ 、R 9’ 、R 10’ 、R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[0088] R 8” 、R 9” 、R 10” 、R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl.

[0089] In one embodiment of the present invention and / or its embodiments, R 7 is independently selected from: hydrogen, C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, hydroxy, NR 8 R 9 、C(=O)OR 10 、SR 10 、SOR 10 、SO 2 R 10 and C(=O)NR 11 R 12 ,

[0090] wherein C 1-6- alkyl, C2-6- An alkenyl group, a 4- to 10-membered heterocyclic group, or a C 1-6- alkoxy group is each optionally substituted independently by one or more substituents selected from the following

[0091] C 1-6- alkyl group, a 5- to 10-membered heterocyclic group, a C 1-6- alkoxy group, a halogen, a cyano group, a hydroxyl group, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[0092] R 8 and R 9 are independently selected from

[0093] hydrogen, C 1-6- alkyl group, C 6-10- aryl group, and a 5- to 10-membered heteroaryl group, or

[0094] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O;

[0095] wherein the C 1-6- alkyl group, C 6-10- aryl group, and a 5- to 10-membered heteroaryl group, or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted independently by one or more substituents selected from the following

[0096] C 1-6- alkyl group, C 1-6- alkoxy group, hydroxyl group, and NR 8” R 9” ;

[0097] R 10 , R 11 and R 12 are independently selected from hydrogen or C 1-6- alkyl group,

[0098] R 8’ , R 9’ , R 10’ , R 11’ and R 12’ are independently selected from hydrogen or C 1-6- alkyl group.

[0099] R 8” and R 9” are independently selected from hydrogen or C1-6- Alkyl

[0100] In one embodiment of the present invention and / or its embodiments, R 7 is independently selected from: methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, mesyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl, and 3,3-difluoroazetidinyl.

[0101] In one embodiment of the present invention and / or its embodiments, R 13 and R 14 together with the atom to which it is attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the ring containing 5 or 6 carbon atoms is optionally substituted by one or more C 1-3 -alkyl or =O, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O-, -S(O)-, -S(O) 2 - or -S-.

[0102] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- alkyl.

[0103] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” are independently C 1-3- alkyl.

[0104] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0105] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0106] In one embodiment of the present invention and / or its embodiments, R13 and R 14 together with the atom to which it is attached form an aromatic ring having 5 or 6 carbon atoms, wherein the ring having 5 or 6 carbon atoms is optionally substituted by one or more C 1-3 -alkyl groups, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[0107] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- alkyl,

[0108] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” are independently C 1-3- alkyl,

[0109] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0110] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0111] In one embodiment of the present invention and / or its embodiments, R 19 is independently selected from C 6-10- aryl and 5- to 10-membered heteroaryl,

[0112] wherein each C 6-10- aryl or 5- to 10-membered heteroaryl is optionally substituted by one or more substituents independently selected from the following

[0113] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 20 R 21 、C(=O)OR 22 and C(=O)NR 23 R24 ,

[0114] R 20 and R 21 are independently selected from

[0115] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, and C 6-10- aryl, or

[0116] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O;

[0117] wherein C 1-6- alkyl, C 3-10- cycloalkyl, or C 6-10- aryl, or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is each optionally substituted independently by one or more substituents selected from

[0118] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’

[0119] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[0120] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl.

[0121] In one embodiment of the present invention and / or its embodiments, R 19 is independently selected from C 6-10- aryl and 5- to 10-membered heteroaryl,

[0122] wherein C 6-10-An aryl or 5- to 10-membered heteroaryl is each optionally substituted by one or more substituents independently selected from the following

[0123] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(=O)OR 22 and C(=O)NR 23 R 24 ,

[0124] R 20 and R 21 are independently selected from

[0125] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[0126] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0127] wherein C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is each optionally substituted by one or more substituents independently selected from the following

[0128] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’

[0129] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[0130] R 20’ , R21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl groups.

[0131] In one embodiment of the present invention and / or its embodiments, R 19 is independently selected from C 6-10- aryl and 5- to 10-membered heteroaryl,

[0132] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted with one or more substituents independently selected from the following

[0133] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, and hydroxyl.

[0134] In one embodiment of the present invention and / or its embodiments, R 19 is C 6-10- aryl, wherein the C 6-10- aryl is optionally substituted with one or more substituents independently selected from the following

[0135] C 1-6- alkyl, halogen, cyano, and nitro.

[0136] In one embodiment of the present invention and / or its embodiments, R 19 is C 6-10- aryl, wherein the C 6-10- aryl is a phenyl group substituted with 1, 2, or 3 substituents independently selected from: fluoride, chloride, and bromide.

[0137] In one embodiment of the present invention and / or its embodiments, R 25 is hydrogen.

[0138] In one embodiment of the present invention and / or its embodiments, the compound according to formula (I) exists in the form of the (S)-enantiomer.

[0139] Furthermore, the present invention provides a method for preparing the compound according to formula (I), which comprises the following steps:

[0140] Reacting a compound of formula (A)

[0141]

[0142] with a compound of formula (B),

[0143] Hal-R 19

[0144] Formula (B)

[0145] wherein

[0146] Hal is a halogen, and

[0147] R 1 、R 7 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 and R 25 are as defined in any one of claims 1 to 13,

[0148] to obtain a compound according to formula (I).

[0149] Furthermore, the present invention provides a veterinary pharmaceutical composition comprising

[0150] - a compound according to formula (I), and

[0151] - one or more physiologically acceptable excipients.

[0152] In one embodiment of the present invention and / or its embodiments, the one or more physiologically acceptable excipients are selected from carriers, fillers, flavoring agents, binders, antioxidants, buffers, sugar components, lubricants, surfactants, stabilizers, glidants, disintegrants and preservatives and mixtures thereof.

[0153] Furthermore, the present invention provides a compound according to formula (I) or a veterinary pharmaceutical composition according to the present invention for use as a medicament.

[0154] Furthermore, the present invention provides a compound according to formula (I) or a veterinary pharmaceutical composition according to the present invention for the treatment of a disorder / disease caused by worms.

[0155] In one embodiment of the present invention and / or its embodiments, the disease is filariasis, particularly heartworm disease.

[0156] In one embodiment of the present invention and / or its embodiments, the worm is Dirofilaria immitis. Detailed Description

[0157] It has been found that the compounds according to formula (I) or their stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof can be used for the treatment of conditions / diseases caused by helminths such as Ostertagia ostertagi, Cooperia oncophora, Cooperia punctata, Trichostrongylus axei, Haemonchus placei, Haemonchus contortus, Nematodirus helvetianus, Nematodirus spathiger, Trichostrongylus colubriformis, Trichostrongylus circumcincta, Oesophagostomum venulosum, Chabertia ovina, Dictyocaulus viviparous, Dictyocaulus filaria, Dirofilaria immitis, Dirofilaria repens; b) trematodes: Fasciola hepatica, Fascioloides magna, Dicrocoelium dendriticum, Paramphistomum cervi, c) cestodes: Monezia expansa. In particular, Ascaridia galli, Haemonchus contortus, Oesophagostomum dentatum and Dirofilaria immitis. Particularly, the compounds according to the invention and / or any of its embodiments can be used for the treatment of helminth infections such as filariasis, in particular heartworm disease. Optionally, the compounds according to the invention and / or any of its embodiments can be used for the treatment of conditions / diseases caused by helminths such as nematodes, in particular Dirofilaria immitis, wherein the condition / disease caused by Dirofilaria immitis is heartworm disease.

[0158] Advantageously, the compounds according to the invention and / or any of its embodiments are effective against worms such as Dirofilaria immitis, but ineffective against bacteria that are particularly relevant to the health of mammals, especially dogs, such as Acinetobacter baumanii or Staphylococcus spp. or Streptococcus spp.

[0159] The inventors have found that the compounds of the invention meet these requirements because they are very useful in the treatment (and prevention) of diseases caused by worms such as heartworm disease.

[0160] The following abbreviations and definitions are used throughout this application.

[0161] Generally, reference to an element means including all isotopes of that element. For example, if a group is defined as including hydrogen or a residue is hydrogen, it also includes deuterium and tritium.

[0162] The term "C 1-6- alkyl" refers to an alkyl group having 1 to 6 carbon atoms and no heteroatoms. Thus, the term includes straight-chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, and hexyl. The term also includes branched-chain isomers of straight-chain alkyl groups, including but not limited to, those provided as examples below: -CH(CH 3 ) 2 、-CH(CH 3 )(CH 2 CH 3 )、-CH(CH 2 CH 3 ) 2 、-C(CH 3 ) 3 、-CH 2 CH(CH 3 ) 2 、-CH 2 CH(CH 2 CH 3 ) 2 、-CH 2 C(CH 3 ) 3 、-CH(CH 3 )CH(CH 3 )(CH 2 CH 3 )、-CH 2 CH 2 CH(CH 3 ) 2 、-CH 2 CH 2 CH(CH 3 )(CH2 CH 3 )、-CH 2 CH 2 C(CH 3 ) 3 etc. Thus, the term "C 1-6- alkyl" includes primary alkyl groups having 1 to 6 carbon atoms, secondary alkyl groups having 3 to 6 carbon atoms, and tertiary alkyl groups having 4 to 6 carbon atoms.

[0163] Accordingly, the term "C 1-3- alkyl" refers to alkyl groups having 1 to 3 carbon atoms and containing no heteroatoms. Thus, the term includes straight-chain alkyl groups such as methyl, ethyl, and propyl. The term also includes branched-chain isomers of straight-chain alkyl groups, i.e., CH(CH 3 ) 2 . Thus, the term "C 1-3- alkyl" includes primary alkyl groups having 1 to 3 carbon atoms and secondary alkyl groups having 3 carbon atoms

[0164] The term "C 2-6 alkenyl" refers to straight-chain and branched-chain alkenyl groups, such as those described above for the "C 2-6 alkyl" defined above, except that there is at least one double bond between two carbon atoms. Examples include, but are not limited to, -CH=CH 2 , -C(CH 3 )=CH 2 , -CH=CH(CH 3 ), -CH=C(CH 3 ) 2 , -CH=CH(CH 3 ), -C(CH 3 )=CH(CH 3 ), -C(CH 2 CH 3 )H=CH 2 , -CH 2 =CH(CH 2 CH 3 ), -CH 2 CH 2 -CH=CH 2 , CH 2 CH 2 -C(CH 3 )=CH 2 , CH 2 CH 2 -CH=C(CH 3 ), -CH=CH-(CH 2 ) 2 CH 3 , -CH=C(CH 3)-CH 2 CH 3 、-(CH 2 ) 3 -CH=CH 2 、-(CH 2 ) 4 -CH=CH 2 、-(CH 2 ) 2 -CH=C(CH 3 ) 2 、butadienyl, pentadienyl, hexadienyl and the like.

[0165] The term "C 2-6- alkynyl" refers to straight-chain and branched alkynyls, such as those described for the "C 2-6- alkyl" defined above, except that there is at least one triple bond between two carbon atoms. Examples include, but are not limited to, -C≡CH, -C≡CCH 3 、-C≡C-CH 2 CH 3 、-CH 2 -C≡CH, -CH(CH 3 )-C≡CH, -C(CH 3 ) 2 -C≡CH, -CH 2 -C≡CCH 3 、-CH(CH 3 )-C≡CCH 3 、-C(CH 3 ) 2 -C≡CCH 3 、-CH 2 -C≡C-CH 2 CH 3 、-CH(CH 3 )-C≡C-CH 2 CH 3 、-C(CH 3 ) 2 -C≡C-CH 2 CH 3 、-(CH 2 ) 2 -C≡C-CH 2 CH 3 、-(CH 2 ) 3 -C≡C-CH 3 and the like.

[0166] The term "C 3-10"-Cycloalkyl" means a non-aromatic monocyclic alkyl group having 3 to 10 carbon atoms or a non-aromatic polycyclic alkyl group having 3 to 10 carbon atoms, wherein said group consists only of carbon and hydrogen atoms. The cycloalkyl group may include a fused ring or a bridged ring system having 3 to 10 carbon atoms. Non-aromatic monocyclic alkyl groups having 3 to 10 carbon atoms include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc. Non-aromatic polycyclic alkyl groups having 3 to 10 carbon atoms include, but are not limited to, adamantane, norbornane, decahydronaphthyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, etc.

[0167] The term "5- to 10-membered heterocyclic group" refers to a cyclic group in which 5 to 10 atoms form a skeleton, wherein the skeleton of the cyclic compound contains at least one carbon atom and at least one heteroatom. Examples of heteroatoms include, but are not limited to, N, O, and S. Unless otherwise specified in the specification, the "5- to 10-membered heterocyclic group" may be a monocyclic, bicyclic or polycyclic group, which may include a fused ring or a bridged ring system, wherein a part of the fused ring system may be aromatic; the nitrogen, carbon or sulfur atoms in the "5- to 10-membered heterocyclic group" may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclic group residue may be partially saturated.

[0168] Examples of heterocyclic groups include, but are not limited to, pyrrolinyl, 3H-pyrazolyl, 4H-pyrazolyl, dihydropyridyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, homopiperazinyl, indolinyl, quinuclidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, dihydrodithienyl, dihydrodisulfinyl, tetrahydrothiophene, tetrahydrothiopyran, benzothiazinyl such as 2H-1,4-benzothiazinyl, dihydrobenzothiazinyl such as 2H-3,4-dihydrobenzothiazinyl, benzodioxolyl such as 1,3-benzodioxolyl, dihydrooxathienyl, 1,4-oxathienyl. Other examples of heterocyclic groups include, but are not limited to, those mentioned above, wherein one or more S atoms in the ring are double-bonded to one or two oxygen atoms (sulfoxides and sulfones), such as tetrahydrothiophene, tetrahydrothiophene oxide and tetrahydrothiophene-1,1-dioxide, and thiomorpholine, thiomorpholine oxide and thiomorpholine-1,1-dioxide.

[0169] The term "C 6-10 Aryl" refers to a group having an aromatic skeletal structure, wherein the ring atoms of the aromatic skeletal structure are carbon atoms. In other words, "C 6-10 Aryl" does not contain heteroatoms such as N, S, O in the aromatic skeletal structure.

[0170] Examples of aryl groups include, but are not limited to, phenyl, biphenyl and naphthyl.

[0171] The term "5- to 10-membered heteroaryl" refers to an aromatic group in which 5 to 10 atoms form a backbone, where the backbone of the cyclic compound contains at least one carbon atom and at least one heteroatom. Examples of heteroatoms include, but are not limited to, N, O, and S. Unless otherwise specifically stated in the specification, "5- to 10-membered heterocyclic group" may be a monocyclic, bicyclic, or polycyclic group, which may include a fused ring system.

[0172] Examples of 5- to 10-membered heteroaryl include, but are not limited to, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl such as 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, and 4H-1,2,4-triazolyl, tetrazolyl such as 1H-tetrazolyl, 2H-tetrazolyl, and 5H-tetrazolyl, indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolinyl, isoquinolinyl, indazolyl, naphthyridinyl, benzotriazolyl, oxazolyl, isoxazolyl, oxadiazolyl such as 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, benzoxazolyl, benzoxadiazolyl, benzoxazinyl such as 2H-1,4-benzoxazinyl, thiazolyl, isothiazolyl, thiadiazolyl such as 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, thienyl, benzothiazolyl, benzothiadiazolyl, benzothiazinyl, benzofuranyl, quinolinyl, isoquinoline, cinnamyl, quinazolinyl, quinoxalinyl, triazinyl, tetrazinyl, purinyl, pteridinyl, furyl, benzodioxolyl such as 1,3-benzodioxolyl, benzothienyl, benzodithienyl, and benzothiazinyl.

[0173] The term "C 1-6- alkoxy" refers to a group based on an alkyl group having 1 to 6 carbon atoms bonded to oxygen. An alkyl group having 1 to 6 carbon atoms refers to straight-chain and branched-chain groups, such as those described for "C 1-6- alkyl" defined above.

[0174] Accordingly, the term "C 1-3- alkoxy" refers to a group based on an alkyl group having 1 to 3 carbon atoms bonded to oxygen. An alkyl group having 1 to 3 carbon atoms refers to straight-chain and branched-chain groups, such as those described for "C 1-3- alkyl" defined above.

[0175] The term "C 1-6- alkylthio" refers to a group based on an alkyl group having 1 to 6 carbon atoms bonded to sulfur. An alkyl group having 1 to 6 carbon atoms refers to straight-chain and branched-chain groups, such as those described for "C 1-6- alkyl" defined above.

[0176] "Optionally substituted" means one or more hydrogens of a group optionally substituted by one or more defined substituents.

[0177] Other amines, hydroxyl groups, and mercapto groups can be protected. The term "protected" with respect to these groups means that the form of these functional groups has a protecting group to prevent unwanted reactions of the groups. These protecting groups are known to those skilled in the art, such as the protecting groups from Organic Synthesis; Wuts, P.G.M. John Wiley & Sons, New York, NY (53rd Edition, 2014). The procedures described therein can be used to add or remove the protecting groups.

[0178] Examples of protected hydroxyl groups include, but are not limited to, silyl ethers, such as those obtained by the reaction of a hydroxyl group with a reagent such as, but not limited to, tert-butyldimethyl-chlorosilane, trimethylchlorosilane, triisopropylchlorosilane, triethylchlorosilane; substituted methyl ethers and ethyl ethers, such as, but not limited to, methoxymethyl ether, methylthiomethyl ether, benzyloxymethyl ether, tert-butoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ether, 1-ethoxyethyl ether, allyl ether, benzyl ether; esters such as, but not limited to, benzoylformate, formate, acetate, trichloroacetate, and trifluoroacetate.

[0179] Examples of protected amino groups include, but are not limited to, amides, such as formamide, acetamide, trifluoroacetamide, and benzamide; imides, such as phthalimide and dithiosuccinimide; carbamates, such as tert-butoxycarbonyl (Boc), etc.

[0180] Examples of protected mercapto groups include, but are not limited to, thioethers, such as S-benzyl thioether and S-4-pyridylmethyl thioether; substituted S-methyl derivatives, such as hemithioacetal, dithioacetal, and aminothioacetal, etc.

[0181] Stereoisomers include compounds composed of the same atoms connected in the same order but with different positions of the atoms in space. Stereoisomers include diastereoisomers and enantiomers.

[0182] "Physiologically acceptable salts" refer to salts formed with inorganic bases, organic bases, inorganic acids, organic acids, or basic or acidic amino acids.

[0183] Examples of suitable inorganic acids for preparing (physiologically acceptable) salts include, but are not limited to, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid, and phosphoric acid.

[0184] Examples of suitable organic acids for preparing (pharmaceutically acceptable) salts include, but are not limited to, cholic acid, sorbic acid, lauric acid, acetic acid, trifluoroacetic acid, formic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, digluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, anthranilic acid, methanesulfonic acid, stearic acid, salicylic acid, p-hydroxybenzoic acid, phenylacetic acid, mandelic acid, pamoic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, pantothenic acid, 2-hydroxyethanesulfonic acid, sulfanilic acid, cyclohexylaminosulfonic acid, β-hydroxybutyric acid, galactaric acid, galacturonic acid, adipic acid, alginic acid, butyric acid, camphoric acid, camphorsulfonic acid, cyclopentanepropionic acid, dodecylsulfuric acid, enanthic acid, glycerophosphoric acid, heptanoic acid, hexanoic acid, nicotinic acid, 2-naphthalenesulfonic acid, oxalic acid, palmitic acid, pectic acid, 3-phenylpropionic acid, picric acid, pivalic acid, thiocyanic acid, toluenesulfonic acid, undecanoic acid, and acidic amino acids such as aspartic acid and glutamic acid.

[0185] Examples of base addition salts can include, for example, metal salts and organic salts.

[0186] Metal salts include, but are not limited to, alkali metal (Group Ia) salts, alkaline earth metal (Group IIa) salts, and other physiologically acceptable metal salts. Examples of such salts can be made from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc. For example, the free acid compound can be mixed with sodium hydroxide to form such a base addition salt.

[0187] Organic salts can be made from amines such as trimethylamine, diethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, ethanolamine, diethanolamine, ethylenediamine, N-methylglucamine, procaine, and basic amino acids such as arginine, lysine, and ornithine.

[0188] As used herein, the term "pharmaceutically acceptable ester" refers to an ester that hydrolyzes in vivo, including those that readily decompose in the human body to leave the parent compound or its salt. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic acids, alkenoic acids, cycloalkanecarboxylic acids, and alkanedioic acids, where each alkyl or alkenyl moiety advantageously has no more than 6 carbon atoms. Representative examples of specific esters include, but are not limited to, formate, acetate, propionate, butyrate, acrylate, and ethyl succinate.

[0189] A solvate of a compound can be considered a compound in which an organic solvent or water is attached to the compound. Organic solvents are those known to the person skilled in the art. If water is attached to the compound, the corresponding compound is called a hydrate.

[0190] As used herein and as generally understood by those skilled in the art, the term "polymorph" refers to different crystalline forms of the same molecular entity. Thus, due to their different chemical compositions, the above-mentioned solvates and hydrates are not included in the definition of polymorphs, but are referred to as "pseudopolymorphs".

[0191] The term "prodrug" refers to a compound that is rapidly converted in vivo to produce the parent compound of formula ((I) above, for example, by hydrolysis in the blood. Detailed discussions are provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Volume 14, A.C.S. Symposium Series and Edward B. Roche, Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987.

[0192] As used herein, the term "pharmaceutically acceptable prodrug" refers to a prodrug of a compound of the present invention that, within the scope of reasonable medical judgment, is suitable for contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., commensurate with a reasonable benefit / risk ratio and effective for its intended use, and, where possible, the zwitterionic form of the compound of the present invention.

[0193] The present invention provides compounds according to the present invention and / or its embodiments, wherein R 1 is as defined above.

[0194] In one embodiment of the present invention and / or its embodiments,

[0195] R 1 is independently selected from

[0196] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 、C(=O)OR 4 and C(=O)NR 5 R 6 ,

[0197] wherein C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0198] C 1-6- alkyl, C 1-6-Alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[0199] R 2 and R 3 are independently selected from

[0200] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[0201] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0202] wherein the C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 2 and R 3 together with the N atom to which they are attached is each optionally substituted with one or more substituents independently selected from

[0203] C 1-6- alkyl, C 3-10- cycloalkyl and C 1-6- alkoxy,

[0204] R 4 , R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[0205] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl.

[0206] Optionally, in one embodiment of the present invention and / or its embodiments,

[0207] R 1 is independently selected from

[0208] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro and C(=O)NR 5 R 6 , wherein the C 1-6- alkyl or C1-6- The alkoxy groups are each optionally independently substituted with one or more substituents selected from the following

[0209] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[0210] R 5 and R 6 are independently selected from hydrogen and C 1-3- alkyl.

[0211] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl.

[0212] Optionally, in one embodiment of the present invention and / or its embodiments,

[0213] R 1 is independently selected from

[0214] hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen,

[0215] wherein the C 1-6- alkyl and C 1-6- alkoxy are each optionally independently substituted with one or more substituents selected from the following

[0216] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[0217] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl.

[0218] In one embodiment of the present invention and / or its embodiments,

[0219] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride.

[0220] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iai), (Iaii) or (Iaiii).

[0221]

[0222]

[0223] or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug thereof, and mixtures thereof, wherein R 7 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 and R 25 are as defined in any of the embodiments described herein.

[0224] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iai), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iaii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iaiii), preferably in the (S)-enantiomeric form.

[0225] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 7 is as defined above.

[0226] In one embodiment of the present invention and / or its embodiments, R 7 is independently selected from hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 、C(=O)OR 10 、SR 10 、SOR 10 、SO 2 R 10 and C(=O)NR 11 R 12 ,

[0227] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0228] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6-Alkoxy, halogen, cyano, hydroxyl, NR 8’ R 9’ 、C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[0229] R 8 and R 9 Independently selected from

[0230] Hydrogen, C 1-6- Alkyl, C 3-10- Cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group and 5- to 10-membered heteroaryl or

[0231] R 8 and R 9 together with the N atom to which it is attached, forms a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0232] Among them C 1-6- Alkyl, C 3-10- Cycloalkyl, C 6-10- Aryl, 5- to 10-membered heterocyclic or 5- to 10-membered heteroaryl or R 8 and R 9 The heterocyclic ring formed together with the N atom to which it is attached is optionally substituted by one or more substituents independently selected from the following

[0233] C 1-6- Alkyl, C 1-6- Alkoxy, halogen, cyano, hydroxyl, NR 8” R 9” 、C(=O)OR 10” and C(=O)NR 11” R 12” ,

[0234] R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[0235] R 8’ , R 9’ , R 10’ , R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[0236] R 8” , R 9” , R 10” , R 11”and R 12” are independently selected from hydrogen and C 1-6- alkyl groups.

[0237] In one embodiment of the present invention and / or its embodiments, wherein R 7 is independently selected from

[0238] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic groups, C 1-6- alkoxy, hydroxy, NR 8 R 9 , C(=O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(=O)NR 11 R 12 ,

[0239] wherein the C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic groups or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0240] C 1-6- alkyl, 5- to 10-membered heterocyclic groups, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[0241] R 8 and R 9 are independently selected from

[0242] hydrogen, C 1-6- alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[0243] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0244] wherein the C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the group formed by R 8 and R 9The heterocyclic ring formed together with the N atom to which it is attached is optionally substituted by one or more substituents independently selected from the following

[0245] C 1-6- Alkyl, C 1-6- Alkoxy, hydroxyl and NR 8” R 9” ,

[0246] R 10 , R 11 and R 12 are independently selected from hydrogen or C 1-6- Alkyl, preferably selected from hydrogen or C 1-3- alkyl,

[0247] R 8’ , R 9’ , R 10’ , R 11’ and R 12’ are independently selected from hydrogen or C 1-6- Alkyl, preferably selected from hydrogen or C 1-3- alkyl,

[0248] R 8” and R 9” are independently selected from hydrogen or C 1-6- Alkyl, preferably selected from hydrogen or C 1-3- alkyl.

[0249] In one embodiment of the present invention and / or its embodiments, R 7 Independently selected from

[0250] Hydrogen, C 1-6- Alkyl, C 2-6- alkenyl, 4 to 10 membered heterocyclic group, C 1-3- Alkoxy, hydroxyl, NR 8 R 9 ,

[0251] Among them C 1-6- Alkyl, C 2-6- alkenyl, 4 to 10 membered heterocyclic group or C 1-3- The alkoxy groups are each optionally substituted with one or more substituents independently selected from the following

[0252] C 1-3- Alkyl, 5- to 10-membered heterocyclic group, C 1-6- Alkoxy, halogen, cyano, hydroxyl, NR 8’ R 9’ ,

[0253] R 8 and R 9 Independently selected from

[0254] Hydrogen, C1-6- alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl, or

[0255] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0256] wherein C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted by one or more substituents independently selected from

[0257] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ,

[0258] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[0259] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl.

[0260] In one embodiment of the present invention and / or its embodiments, R 7 is independently selected from

[0261] methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methanesulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl, preferably dimethylamino and morpholin-4-yl.

[0262] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ibi), (Ibii), (Ibiii), (Ibiv), (Ibv), (Ibvi), (Ibvii), (Ibvii), (Ibix), (Ibx) or (Ibxi)

[0263]

[0264]

[0265]

[0266] or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug thereof, and mixtures thereof, wherein R 1 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 and R 25 are as defined in any one of the embodiments described herein.

[0267] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ibi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ibii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ibiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ibiv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ibv), preferably in the (S)-enantiomeric form.

[0268] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ibvi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ibvii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ibviii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ibix), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ibx), preferably in the (S)-enantiomeric form.

[0269] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ibxi), preferably in the (S)-enantiomeric form.

[0270] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 13 and R 14and R 15 、R 16 、R 17 and R 18 as defined above.

[0271] In one embodiment of the present invention and / or its embodiments,

[0272] R 13 is hydrogen or C 1-3 alkyl, and

[0273] R 14 is hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0274] More preferably, in one embodiment of the present invention and / or its embodiments,

[0275] R 13 is hydrogen or C 1-3 alkyl, and

[0276] R 14 is hydrogen or C 1-3 alkyl.

[0277] More preferably, in one embodiment of the present invention and / or its embodiments,

[0278] R 13 is hydrogen, methyl or ethyl, preferably hydrogen or methyl, and

[0279] R 14 is hydrogen or methyl, preferably hydrogen.

[0280] In another embodiment of the present invention and / or its embodiments,

[0281] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- alkyl,

[0282] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” are independently C 1-3- alkyl,

[0283] R17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0284] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0285] In another embodiment of the present invention and / or its embodiments,

[0286] R 13 is hydrogen or C 1-3- alkyl,

[0287] R 14 is hydrogen, C 1-3- alkyl or C 1-3- alkoxy,

[0288] R 15 is hydrogen halide, C 1-3- alkyl, C 1-3- alkoxy or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- alkyl,

[0289] R 16 is hydrogen halide, C 1-3- alkyl, C 1-3- alkoxy or NR 16’ R 16” wherein R 16’ and R 16” are independently C 1-3- alkyl,

[0290] R 17 is hydrogen or C 1-3- alkyl,

[0291] R 18 is hydrogen or C 1-3- alkyl.

[0292] In another embodiment of the present invention and / or its embodiments,

[0293] R 13 is hydrogen, methyl or ethyl, preferably hydrogen or methyl,

[0294] R 14 is hydrogen or methyl, preferably hydrogen,

[0295] R 15 is hydrogen or C 1-3 alkyl, preferably hydrogen or methyl,

[0296] R 16 is hydrogen or C 1-3 alkyl, preferably hydrogen or methyl,

[0297] R 17 and R 18 is hydrogen.

[0298] In another embodiment of the present invention and / or its embodiments,

[0299] R 13 is hydrogen, methyl or ethyl, preferably hydrogen or methyl,

[0300] R 14 is hydrogen or methyl, preferably hydrogen,

[0301] R 15 、R 16 、R 17 and R 18 is hydrogen.

[0302] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ic).

[0303]

[0304] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 1 、R 7 、R 19 and R 25 are defined as in any of the embodiments described herein.

[0305] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ic), preferably in the (S)-enantiomeric form.

[0306] In one embodiment of the present invention and / or its embodiments, R 13 and R 14 together with the atoms to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the ring containing 5 or 6 carbon atoms is optionally substituted by one or more C 1-3 -alkyl or =O, and / or wherein one or more of the carbon atoms forming the ring are optionally substituted by -NH-, -N=, =N-, -O-, -S(O)-, -S(O) 2 - or -S-; or

[0307] R 13 and R 14 together with the atoms to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally substituted by one or more C 1-3-Alkyl substitution, and / or one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-.

[0308] Examples of non-aromatic or aromatic rings containing 5 or 6 carbon atoms, wherein the non-aromatic ring containing 5 or 6 carbon atoms is optionally substituted by one or more C 1-3 -alkyl or =O, and / or one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O-, -S(O)-, -S(O) 2 - or -S-; or the aromatic ring containing 5 or 6 carbon atoms is optionally substituted by one or more C 1-3 -alkyl, and / or one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-, including but not limited to residues represented by the following structures

[0309]

[0310] wherein

[0311] represents bonding to an amide group; and

[0312] represents the bond of the above ring system fused to an aromatic ring.

[0313] In one embodiment of the present invention and / or its embodiments,

[0314] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the non-aromatic ring is optionally substituted by one or more C 1-3- -alkyl or =O, and / or one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, -S(O)-, -S(O) 2 - or -S-,

[0315] R 15 is independently hydrogen, halogen, C 1-3 -alkyl, C 1-3 -alkoxy or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- -alkyl,

[0316] R 16 is independently hydrogen, halogen, C 1-3 -alkyl, C 1-3 -alkoxy or NR 16’ R 16”, where R 16’ and R 16” are independently C 1-3- alkyl,

[0317] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0318] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 .

[0319] In one embodiment of the present invention and / or its embodiments,

[0320] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O- or -S-,

[0321] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0322] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0323] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0324] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0325] In one embodiment of the present invention and / or its embodiments,

[0326] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH- or -O-,

[0327] R 15 is independently hydrogen or C 1-3 alkoxy,

[0328] R 16 is independently hydrogen or C 1-3 alkoxy,

[0329] R 17 is independently hydrogen or C 1-3 alkoxy,

[0330] R 18 is independently hydrogen or C 1-3 alkoxy.

[0331] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Idi), (Idii), (Idiii) or (Idiv).

[0332]

[0333]

[0334] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 1 , R 7 , R 19 and R 25 are defined as in any of the embodiments described herein.

[0335] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Idi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Idii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Idiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Idiv), preferably in the (S)-enantiomeric form.

[0336] In one embodiment of the present invention and / or its embodiments,

[0337] R 13 and R 14 together with the atoms to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally substituted by one or more C 1-3 -alkyl, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[0338] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” , wherein R 15’ and R 15” are independently C1-3- alkyl

[0339] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” are independently C 1-3- alkyl

[0340] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0341] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0342] In one embodiment of the present invention and / or its embodiments,

[0343] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-

[0344] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0345] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0346] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0347] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0348] In one embodiment of the present invention and / or its embodiments,

[0349] R 13 and R 14Together with the atom to which it is attached, form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N- or -S-.

[0350] R 15 is independently hydrogen or C 1-3 alkoxy,

[0351] R 16 is independently hydrogen or C 1-3 alkoxy,

[0352] R 17 is independently hydrogen or C 1-3 alkoxy,

[0353] R 18 is independently hydrogen or C 1-3 alkoxy.

[0354] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Idv), (Idvi) or (Idvii)

[0355]

[0356] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 1 , R 7 , R 19 and R 25 are defined as in any of the embodiments described herein.

[0357] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Idv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Idvi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Idvii), preferably in the (S)-enantiomeric form.

[0358] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 19 is as defined above.

[0359] In one embodiment of the present invention and / or its embodiments, R 19 is independently selected from

[0360] C 6-10- aryl and 5- to 10-membered heteroaryl,

[0361] wherein C 6-10-An aryl or 5- to 10-membered heteroaryl is each optionally substituted by one or more substituents independently selected from the following

[0362] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(=O)OR 22 and C(=O)NR 23 R 24 ,

[0363] R 20 and R 21 are independently selected from

[0364] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[0365] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0366] wherein C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is each optionally substituted by one or more substituents independently selected from the following

[0367] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’

[0368] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[0369] R 20’ , R21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl groups.

[0370] In one embodiment of the present invention and / or its embodiments, R 19 is independently selected from C 6-10- aryl and 5- to 10-membered heteroaryl,

[0371] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted with one or more substituents independently selected from the following

[0372] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, C(=O)OR 22 , SO 2 R 22 , SO 2 NR 23 R 24 and C(=O)NR 23 R 24 .

[0373] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl groups.

[0374] In one embodiment of the present invention and / or its embodiments, R 19 is independently selected from C 6-10- aryl and 5- to 10-membered heteroaryl,

[0375] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted with one or more substituents independently selected from the following

[0376] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, C(=O)OR 22 and C(=O)NR 23 R 24 .

[0377] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl groups.

[0378] In one embodiment of the present invention and / or its embodiments, R 19 is independently selected from C 6-10- aryl and 5- to 10-membered heteroaryl

[0379] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted with one or more substituents independently selected from the following

[0380] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, and hydroxy.

[0381] In one embodiment of the present invention and / or its embodiments, R 19 is a 5- to 10-membered heteroaryl

[0382] wherein the 5- to 10-membered heteroaryl is optionally substituted with one or more substituents independently selected from the following

[0383] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, and hydroxy.

[0384] In one embodiment of the present invention and / or its embodiments, R 19 is a 5- to 10-membered heteroaryl

[0385] wherein the 5- to 10-membered heteroaryl is optionally substituted with one or more substituents independently selected from the following

[0386] C 1-6- alkyl and halogen, preferably hydrogen.

[0387] Examples of 5- to 10-membered heteroaryl groups include, but are not limited to, pyrrolyl, imidazolyl, pyrazolyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl, pyrazinyl, pyridazinyl, triazolyl such as 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, and 4H-1,2,4-triazolyl, tetrazolyl such as 1H-tetrazolyl, 2H-tetrazolyl, and 5H-tetrazolyl, indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolin-4-yl, quinolin-8-yl, isoquinolinyl, indazolyl, naphthyridinyl, benzotriazolyl, oxazolyl, isoxazolyl, oxadiazolyl such as 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, benzoxazolyl, benzoxadiazolyl, benzoxazinyl such as 2H-1,4-benzoxazinyl, thiazolyl, isothiazolyl, thiadiazolyl such as 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, thiophen-2-yl, thiophen-3-yl, benzothiazolyl, benzothiadiazolyl, benzothiazinyl, benzofuranyl, quinolinyl, isoquinolinyl, cinnamyl, quinazolinyl, quinoxalinyl, triazinyl, tetrazinyl, purinyl, pteridinyl, furyl, benzodioxolyl such as 1,3-benzodioxolyl, benzothiophenyl, benzodithiophenyl, and benzoxathiophenyl. Preferred are pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl, quinolin-8-yl, thiophen-2-yl, and thiophen-3-yl.

[0388] In one embodiment of the present invention and / or its embodiments, R 19 is a 5- to 10-membered heteroaryl,

[0389] wherein the 5- to 10-membered heteroaryl is substituted with one or more substituents independently selected from the following

[0390] C 1-6- alkyl and halogen, preferably halogen.

[0391] In one embodiment of the present invention and / or its embodiments, wherein R 19 is C 6-10- aryl,

[0392] wherein the C 6-10 aryl is optionally substituted with one or more substituents independently selected from the following

[0393] C 1-6- alkyl, halogen, cyano, and nitro.

[0394] In one embodiment of the present invention and / or its embodiments, wherein R 19 is C 6-10- aryl,

[0395] wherein C 6-10 The aryl is a phenyl group substituted by one, two or three substituents independently selected from fluoride, chloride and bromide.

[0396] Examples of phenyl groups substituted by one, two or three substituents independently selected from fluoride, chloride and bromide include, but are not limited to, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,3-dibromophenyl, 2,4-dibromophenyl, 2,5-dibromophenyl, 3,4-dibromophenyl, 3,5-dibromophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 3,4,5-trifluorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 3,4,5-trichlorophenyl, 2,3,4-tribromophenyl, 2,3,5-tribromophenyl, 3,4,5-tribromophenyl, 2-chloro-3-fluorophenyl, 2-chloro-4-fluorophenyl, 2-chloro-5-fluorophenyl, 3-chloro-2-fluorophenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 4-chloro-2-fluorophenyl, 4-chloro-3-fluorophenyl, 4-chloro-5-fluorophenyl, 5-chloro-2-fluorophenyl, 5-chloro-3-fluorophenyl, 5-chloro-4-fluorophenyl, 3-bromo-2-fluorophenyl, 4-bromo-2-chlorobromophenyl, 4-bromo-3-chlorophenyl, 3,4-dichloro-2-fluorophenyl, 3,5-dichloro-2-fluorophenyl, 3,5-dichloro-4-fluorophenyl, 4,5-dichloro-3-fluorophenyl, 3,4-dibromo-2-fluorophenyl, 3,5-dibromo-2-fluorophenyl, 4,5-dibromo-3-fluorophenyl, 2-chloro-3,4-difluorophenyl, 2-chloro-3,5-difluorophenyl, 3-chloro-4,5-difluorophenyl, 3,4-dibromo-2-chlorophenyl, 3,5-dibromo-2-chlorophenyl, 4,5-dibromo-3-chlorophenyl, 2-bromo-3,4-difluorophenyl, 2-bromo-3,5-difluorophenyl, 3-bromo-4,5-difluorophenyl, 2-bromo-3,4-dichlorophenyl, 2-bromo-3,5-dichlorophenyl, 3-bromo-4,5-dichlorophenyl, 4-bromo-3-chloro-2-fluorophenyl, 4-bromo-2-chloro-3-fluorophenyl, 2-bromo-3-chloro-4-fluorophenyl, 5-bromo-3-chloro-2-fluorophenyl, 5-bromo-2-chloro-3-fluorophenyl, 2-bromo-3-chloro-5-fluorophenyl, 5-bromo-4-chloro-3-fluorophenyl, 5-bromo-3-chloro-4-fluorophenyl and 3-bromo-4-chloro-5-fluorophenyl.

[0397] Preferably 3-fluorophenyl, 3-chlorophenyl, 2,3-difluorophenyl, 3,5-difluorophenyl, 2,3-dichlorophenyl, 3,5-dichlorophenyl, 2-chloro-3-fluorophenyl, 3-chloro-2-fluorophenyl, 5-chloro-3-fluorophenyl, 5-chloro-3-fluorophenyl, 5-chloro-2-fluorophenyl, 3,4,5-trifluorophenyl, 2,3,5-trifluorophenyl, 3,5-dichloro-4-fluorophenyl and 3,4,5-trichlorophenyl, more preferably 3-chlorophenyl, 2,3-dichlorophenyl, 3,5-dichlorophenyl, 3,5-difluorophenyl, 2,3,5-trifluorophenyl, 3,4,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 5-chloro-3-fluorophenyl, 5-chloro-3-fluorophenyl, 3,5-dichloro-4-fluorophenyl, especially 2,3,5-trifluorophenyl, 5-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl.

[0398] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iei), (Ieii), (Ieiii), (Ieiv), (Iev), (Ievi), (Ievii), (Ieviii), (Ieix) or (Iex)

[0399]

[0400]

[0401]

[0402]

[0403] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 1 、R 7 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 and R 25 are defined as in any of the embodiments described herein.

[0404] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iei), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ieii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ieiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ieiv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iev), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ievi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ievii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ieviii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ieix), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iex), preferably in the (S)-enantiomeric form.

[0405] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 25 is as defined above.

[0406] In one embodiment of the present invention and / or its embodiments, R 25 is hydrogen or methyl.

[0407] In one embodiment of the present invention and / or its embodiments, R 25 is hydrogen.

[0408] In one embodiment of the present invention and / or its embodiments, the compound is as shown in formula (If)

[0409]

[0410] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 1 、R 7 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 and R 19As defined in any of the embodiments described herein.

[0411] In one embodiment of the invention and / or its embodiments, the compound is according to formula (Ifi), preferably in the (S)-enantiomeric form.

[0412] The invention provides a compound according to the invention and / or its embodiments, wherein R 1 and R 7 As defined above.

[0413] In one embodiment of the invention and / or its embodiments,

[0414] R 1 is independently selected from

[0415] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(=O)OR 4 and C(=O)NR 5 R 6 ,

[0416] wherein the C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from

[0417] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[0418] R 2 and R 3 are independently selected from

[0419] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[0420] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0421] wherein the C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or formed by R 2 and R3 The heterocycles formed together with the N atoms to which they are attached are each optionally substituted with one or more substituents independently selected from the following

[0422] C 1-6- alkyl, C 3-10- cycloalkyl and C 1-6- alkoxy,

[0423] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[0424] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[0425] and

[0426] R 7 is independently selected from

[0427] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 、C(=O)OR 10 、SR 10 、SOR 10 、SO 2 R 10 and C(=O)NR 11 R 12 ,

[0428] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0429] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ 、C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[0430] R 8 and R 9 are independently selected from

[0431] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, and 5- to 10-membered heteroaryl; or

[0432] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O;

[0433] wherein the C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, or 5- to 10-membered heteroaryl; or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from

[0434] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” 、C(=O)OR 10” and C(=O)NR 11” R 12”

[0435] R 10 、R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[0436] R 8’ 、R 9’ 、R 10’ 、R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[0437] R 8” 、R 9” 、R 10” 、R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl.

[0438] Optionally, in one embodiment of the present invention and / or its embodiments,

[0439] R 1 are independently selected from

[0440] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, and halogen,

[0441] wherein the C 1-6- alkyl and C 1-6- alkoxy are each optionally substituted with one or more substituents independently selected from

[0442] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, and NR 2’ R 3’ ,

[0443] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl,

[0444] and

[0445] R 7 is independently selected from

[0446] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, a 4- to 10-membered heterocyclic group, C 1-3- alkoxy, hydroxy, NR 8 R 9 ,

[0447] wherein the C 1-6- alkyl, C 2-6- alkenyl, the 4- to 10-membered heterocyclic group, or C 1-3- alkoxy is each optionally substituted with one or more substituents independently selected from

[0448] C 1-3- alkyl, a 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ ,

[0449] R 8 and R 9 are independently selected from

[0450] hydrogen, C 1-6- alkyl, C 6-10- aryl, and a 5- to 10-membered heteroaryl, or

[0451] R 8 and R 9Together with the N atom to which it is attached, form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 1 ring atom is N and 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0452] wherein C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 Together with the N atom to which it is attached, the formed heterocycle is optionally substituted with one or more substituents independently selected from the following

[0453] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ;

[0454] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[0455] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl.

[0456] In one embodiment of the present invention and / or its embodiments,

[0457] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride,

[0458] and

[0459] R 7 is independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methanesulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl.

[0460] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Igi), (Igii), (Igiii) or (Igiv)

[0461]

[0462]

[0463] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs, and mixtures thereof, wherein R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 25 are as defined in any of the embodiments described herein.

[0464] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Igi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Igii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Igiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Igiv), preferably in the (S)-enantiomeric form.

[0465] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 1 and R 13 , R 14 , R 15 , R 16 , R 17 and R 18 are as defined above.

[0466] In one embodiment of the present invention and / or its embodiments,

[0467] R 1 is independently selected from

[0468] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(=O)OR 4 and C(=O)NR 5 R 6 ,

[0469] wherein C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0470] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’R 3’ and

[0471] R 2 and R 3 are independently selected from

[0472] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, and 5- to 10-membered heteroaryl; or

[0473] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O;

[0474] wherein the C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heteroaryl, or the heterocycle formed by R 2 and R 3 together with the N atom to which they are attached is each optionally substituted with one or more substituents independently selected from

[0475] C 1-6- alkyl, C 3-10- cycloalkyl, and C 1-6- alkoxy;

[0476] R 4 , R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl;

[0477] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl;

[0478] and

[0479] R 13 and R 14 together with the atoms to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the non-aromatic ring is optionally substituted with one or more C 1-3- alkyl or ═O, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, -S(O)-, -S(O) 2 2-, or -S-;

[0480] R 15Independently is hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- alkyl,

[0481] R 16 Independently is hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” are independently C 1-3- alkyl,

[0482] R 17 Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0483] R 18 Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0484] Optionally, in one embodiment of the present invention and / or its embodiments,

[0485] R 1 is independently selected from

[0486] hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen,

[0487] wherein C 1-6- alkyl and C 1-6- alkoxy are optionally substituted by one or more substituents independently selected from C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[0488] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl,

[0489] and

[0490] R 13 and R 14Together with the atom to which it is attached, form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O- or -S-.

[0491] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0492] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0493] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0494] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0495] In one embodiment of the present invention and / or its embodiments,

[0496] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride,

[0497] and

[0498] R 13 and R 14 together with the atom to which it is attached, form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH- or -O-.

[0499] R 15 is independently hydrogen or C 1-3 alkoxy.

[0500] R 16 is independently hydrogen or C 1-3 alkoxy.

[0501] R 17 is independently hydrogen or C 1-3 alkoxy.

[0502] R 18 is independently hydrogen or C 1-3 alkoxy.

[0503] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ihi), (Ihii), (Ihiii), (Ihiv), (Ihv) or (Ihvi)

[0504]

[0505]

[0506] or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug, and mixtures thereof, wherein R 7 、R 19 and R 25 are as defined in any of the embodiments described herein.

[0507] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ihi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ihii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ihiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ihiv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ihv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ihvi), preferably in the (S)-enantiomeric form.

[0508] In one embodiment of the present invention and / or its embodiments,

[0509] R 1 is independently selected from

[0510] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 、C(=O)OR 4 and C(=O)NR 5 R 6 ,

[0511] wherein the C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0512] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, and NR 2’ R 3’ ,

[0513] R2 and R 3 are independently selected from

[0514] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, and 5- to 10-membered heteroaryl, or

[0515] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O;

[0516] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, or 5- to 10-membered heteroaryl, or the heterocycle formed by R 2 and R 3 together with the N atom to which they are attached is each optionally substituted with one or more substituents independently selected from

[0517] C 1-6- alkyl, C 3-10- cycloalkyl, and C 1-6- alkoxy,

[0518] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[0519] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[0520] and

[0521] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally substituted with one or more C 1-3- alkyl, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O-, or -S-,

[0522] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 15’ R 15” wherein R15’ and R 15” is independently C 1-3- alkyl

[0523] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” is independently C 1-3- alkyl

[0524] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0525] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0526] Optionally, in one embodiment of the present invention and / or its embodiments,

[0527] R 1 is independently selected from

[0528] hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen

[0529] wherein C 1-6- alkyl and C 1-6- alkoxy are optionally substituted by one or more substituents independently selected from the following

[0530] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[0531] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl

[0532] and

[0533] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-

[0534] R 15Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0535] wherein R 16 independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0536] wherein R 17 independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0537] wherein R 18 independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0538] In one embodiment of the present invention and / or its embodiments,

[0539] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride, and chloride,

[0540] and

[0541] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, or -S-,

[0542] R 15 is independently hydrogen or C 1-3 alkoxy,

[0543] R 16 is independently hydrogen or C 1-3 alkoxy,

[0544] R 17 is independently hydrogen or C 1-3 alkoxy,

[0545] R 18 is independently hydrogen or C 1-3 alkoxy.

[0546] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ihvii), (Ihviii), (Ihix), or (Ihx)

[0547]

[0548]

[0549] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs, and mixtures thereof, wherein R 7 and R 19 and R 25 are as defined in any of the embodiments described herein.

[0550] In one embodiment of the invention and / or its embodiments, the compound is according to formula (Ihvii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Ihviii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Ihix), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Ihx), preferably in the (S)-enantiomeric form.

[0551] The invention provides a compound according to the invention and / or its embodiments, wherein R 1 and R 19 are as defined above.

[0552] In one embodiment of the invention and / or its embodiments,

[0553] R 1 is independently selected from

[0554] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(=O)OR 4 and C(=O)NR 5 R 6 ,

[0555] wherein C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from

[0556] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[0557] R 2 and R 3 are independently selected from

[0558] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10-Aryl and 5- to 10-membered heteroaryl or

[0559] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0560] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 2 and R 3 together with the N atom to which they are attached is each optionally substituted by one or more substituents independently selected from

[0561] C 1-6- alkyl, C 3-10- cycloalkyl and C 1-6- alkoxy,

[0562] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[0563] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[0564] and

[0565] R 19 is independently selected from

[0566] C 6-10- aryl and 5- to 10-membered heteroaryl,

[0567] wherein C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted by one or more substituents independently selected from

[0568] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 、C(=O)OR 22 and C(=O)NR 23 R 24,

[0569] R 20 and R 21 are independently selected from

[0570] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, and C 6-10- aryl, or

[0571] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O;

[0572] wherein C 1-6- alkyl, C 3-10- cycloalkyl, or C 6-10- aryl, or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is each optionally substituted independently by one or more substituents selected from

[0573] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’

[0574] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[0575] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl.

[0576] Optionally, in one embodiment of the present invention and / or its embodiments,

[0577] R 1 is independently selected from

[0578] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, and halogen,

[0579] Wherein C 1-6- alkyl and C 1-6- alkoxy are optionally independently substituted with one or more substituents selected from the following

[0580] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxyl and NR 2’ R 3’ ,

[0581] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl,

[0582] and

[0583] R 19 is C 6-10- aryl,

[0584] wherein C 6-10 aryl is phenyl substituted with one, two or three substituents independently selected from the following: fluoride, chloride and bromide.

[0585] In one embodiment of the present invention and / or its embodiments,

[0586] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride,

[0587] and

[0588] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl.

[0589] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iii), (Iiii), (Iiiii), (Iiiv), (Iiv) or (Iivi)

[0590]

[0591]

[0592] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 7 , R 13 , R 14 , R 15 , R 16 , R17 , R 18 and R 25 as defined in any of the embodiments described herein.

[0593] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iiiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iiiv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iiv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iivi), preferably in the (S)-enantiomeric form.

[0594] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 1 and R 25 are as defined above.

[0595] In one embodiment of the present invention and / or its embodiments,

[0596] R 1 is independently selected from

[0597] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(=O)OR 4 and C(=O)NR 5 R 6 ,

[0598] wherein the C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0599] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[0600] R 2 and R 3 are independently selected from

[0601] Hydrogen, C 1-6- Alkyl, C 3-10- Cycloalkyl, C 6-10- Aryl and 5- to 10-membered heteroaryl or

[0602] R 2 and R 3 together with the N atom to which it is attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0603] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 2 and R 3 together with the N atom to which it is attached is each optionally substituted with one or more substituents independently selected from

[0604] C 1-6- alkyl, C 3-10- cycloalkyl and C 1-6- alkoxy,

[0605] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[0606] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[0607] and

[0608] R 25 is hydrogen or methyl, preferably hydrogen.

[0609] Optionally, in one embodiment of the present invention and / or its embodiments,

[0610] R 1 is independently selected from

[0611] hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen,

[0612] wherein C 1-6- alkyl and C 1-6- alkoxy are each optionally substituted with one or more substituents independently selected from

[0613] C1-6- Alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, and NR 2’ R 3’ ,

[0614] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl,

[0615] and

[0616] R 25 is hydrogen or methyl, preferably hydrogen.

[0617] In one embodiment of the present invention and / or its embodiments,

[0618] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride, and chloride,

[0619] and

[0620] R 25 is hydrogen or methyl, preferably hydrogen.

[0621] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iji) or (Ijii)

[0622]

[0623] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs, and mixtures thereof, wherein R 7 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are defined as in any of the embodiments described herein.

[0624] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iji), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ijii), preferably in the (S)-enantiomeric form.

[0625] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 7 and R 13 , R 14 , R 15 , R 16 , R17 and R 18 as defined above.

[0626] In one embodiment of the present invention and / or its embodiments,

[0627] R 7 is independently selected from

[0628] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 , C(=O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(=O)NR 11 R 12 ,

[0629] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0630] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[0631] R 8 and R 9 are independently selected from

[0632] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group and 5- to 10-membered heteroaryl or

[0633] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0634] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, a 5- to 10-membered heterocyclic group or a 5- to 10-membered heteroaryl group, or a heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted by one or more substituents independently selected from the following

[0635] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” 、C(=O)OR 10” and C(=O)NR 11” R 12”

[0636] R 10 、R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[0637] R 8’ 、R 9’ 、R 10’ 、R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[0638] R 8” 、R 9” 、R 10” 、R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl,

[0639] and

[0640] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the non-aromatic ring is optionally substituted by one or more C 1-3- alkyl or =O, and / or one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, -S(O)-, -S(O) 2 - or -S-,

[0641] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” wherein R 15’ and R 15”Independently is C 1-3- alkyl

[0642] R 16 Independently is hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” Independently is C 1-3- alkyl

[0643] R 17 Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0644] R 18 Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0645] In one embodiment of the present invention and / or its embodiments,

[0646] R 7 Independently selected from

[0647] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group, C 1-3- alkoxy, hydroxyl, NR 8 R 9 ,

[0648] wherein C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group or C 1-3- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0649] C 1-3- alkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxyl, NR 8’ R 9’ ,

[0650] R 8 and R 9 Independently selected from

[0651] hydrogen, C 1-6- alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[0652] R 8 and R 9Together with the N atom to which it is attached, form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0653] wherein C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which it is attached is optionally substituted by one or more substituents independently selected from the following

[0654] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ,

[0655] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[0656] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[0657] and

[0658] R 13 and R 14 together with the atom to which it is attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O- or -S-,

[0659] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0660] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0661] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0662] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0663] In one embodiment of the present invention and / or its embodiments,

[0664] R 7 is independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, mesyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl, and 3,3-difluoroazetidinyl,

[0665] and

[0666] R 13 and R 14 together with the atom to which it is attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH- or -O-,

[0667] R 15 is independently hydrogen or C 1-3 alkoxy,

[0668] R 16 is independently hydrogen or C 1-3 alkoxy,

[0669] R 17 is independently hydrogen or C 1-3 alkoxy,

[0670] R 18 is independently hydrogen or C 1-3 alkoxy.

[0671] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iki), (Ikii), (Ikiii), (Ikiv), (Ikv) or (Ikvi)

[0672]

[0673]

[0674] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 1 、R 19 and R 25 are defined as in any of the embodiments described herein.

[0675] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iki), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ikii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ikiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ikiv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ikv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ikvi), preferably in the (S)-enantiomeric form.

[0676] In one embodiment of the present invention and / or its embodiments,

[0677] R 7 is independently selected from

[0678] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 , C(=O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(=O)NR 11 R 12 ,

[0679] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0680] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[0681] R8 and R 9 are independently selected from

[0682] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, and 5- to 10-membered heteroaryl; or

[0683] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O,

[0684] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, or 5- to 10-membered heteroaryl; or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from

[0685] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” 、C(=O)-OR 10” and C(=O)NR 11” R 12”

[0686] R 10 、R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[0687] R 8’ 、R 9’ 、R 10’ 、R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[0688] R 8” 、R 9” 、R 10” 、R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl,

[0689] and

[0690] R 13 and R 14Together with the atom to which it is attached, form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally substituted by one or more C 1-3- alkyl groups, and / or wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[0691] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- alkyl,

[0692] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” are independently C 1-3- alkyl,

[0693] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0694] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3- alkoxy.

[0695] In one embodiment of the present invention and / or its embodiments,

[0696] R 7 is independently selected from

[0697] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group, C 1-3- alkoxy, hydroxy, NR 8 R 9 ,

[0698] wherein C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group or C 1-3- alkoxy is each optionally substituted by one or more substituents independently selected from the following

[0699] C 1-3- alkyl, 5- to 10-membered heterocyclic group, C 1-6-Alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ ,

[0700] R 8 and R 9 are independently selected from

[0701] hydrogen, C 1-6- alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[0702] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0703] wherein the C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from

[0704] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ,

[0705] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[0706] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[0707] and

[0708] R 13 and R 14 together with the atoms to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[0709] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0710] R 16 is independently hydrogen, C 1-3Alkyl or C 1-3 alkoxy,

[0711] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0712] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0713] In one embodiment of the present invention and / or its embodiments,

[0714] R 7 is independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methanesulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl, and 3,3-difluoroazetidinyl,

[0715] and

[0716] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N- or -S-,

[0717] R 15 is independently hydrogen or C 1-3 alkoxy,

[0718] R 16 is independently hydrogen or C 1-3 alkoxy,

[0719] R 17 is independently hydrogen or C 1-3 alkoxy,

[0720] R 18 is independently hydrogen or C 1-3 alkoxy.

[0721] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ikvii), (Ikviii), (Ikix) or (Ikx)

[0722]

[0723] or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug thereof, and mixtures thereof, wherein R 1 and R 19 and R 25 are as defined in any of the embodiments described herein.

[0724] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ikvii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ikviii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ikix), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ikx), preferably in the (S)-enantiomeric form.

[0725] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 7 and R 19 are as defined above.

[0726] In one embodiment of the present invention and / or its embodiments,

[0727] R 7 is independently selected from

[0728] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 , C(=O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(=O)NR 11 R 12 ,

[0729] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[0730] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6-alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[0731] R 8 and R 9 are independently selected from

[0732] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, and 5- to 10-membered heteroaryl; or

[0733] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O,

[0734] wherein the C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, or 5- to 10-membered heteroaryl; or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from

[0735] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” , C(=O)-OR 10” and C(=O)NR 11” R 12” ,

[0736] R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[0737] R 8’ , R 9’ , R 10’ , R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[0738] R 8” , R 9” , R 10” , R11” and R 12” are independently selected from hydrogen and C 1-6- alkyl

[0739] and

[0740] R 19 is independently selected from

[0741] C 6-10- aryl and 5- to 10-membered heteroaryl

[0742] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted with one or more substituents independently selected from

[0743] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(=O)OR 22 and C(=O)NR 23 R 24 ,

[0744] R 20 and R 21 are independently selected from

[0745] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[0746] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O

[0747] wherein the C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is each optionally substituted with one or more substituents independently selected from

[0748] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’R 21’ 、C(=O)OR 22’ and C(=O)NR 23’ R 24’

[0749] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[0750] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl.

[0751] In one embodiment of the present invention and / or its embodiments,

[0752] R 7 Independently selected from

[0753] Hydrogen, C 1-6- Alkyl, C 2-6- alkenyl, 4 to 10 membered heterocyclic group, C 1-3- Alkoxy, hydroxyl, NR 8 R 9 ,

[0754] Among them C 1-6- Alkyl, C 2-6- alkenyl, 4 to 10 membered heterocyclic group or C 1-3- The alkoxy groups are each optionally substituted with one or more substituents independently selected from the following

[0755] C 1-3- Alkyl, 5- to 10-membered heterocyclic group, C 1-6- Alkoxy, halogen, cyano, hydroxyl, NR 8’ R 9’ ,

[0756] R 8 and R 9 Independently selected from

[0757] Hydrogen, C 1-6- Alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[0758] R 8 and R 9 together with the N atom to which it is attached, forms a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0759] wherein C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or a heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the following

[0760] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ,

[0761] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[0762] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[0763] and

[0764] R 19 is C 6-10- aryl,

[0765] wherein C 6-10 aryl is phenyl substituted with one, two or three substituents independently selected from: fluoride, chloride and bromide.

[0766] In one embodiment of the present invention and / or its embodiments,

[0767] R 7 is independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methanesulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl,

[0768] and

[0769] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl.

[0770] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ili), (Ilii), (Iliii), (Iliv), (Ilv) or (Ilvi)

[0771]

[0772]

[0773] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 1 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 and R 25 are defined in any of the embodiments described herein.

[0774] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ili), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ilii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iliii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iliv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ilv). In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ilvi), preferably in the (S)-enantiomeric form.

[0775] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 7 and R 25 are as defined above.

[0776] In one embodiment of the present invention and / or its embodiments

[0777] R 7 is independently selected from

[0778] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 、C(=O)OR10 , SR 10 , SOR 10 , SO 2 R 10 and C(=O)NR 11 R 12 ,

[0779] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally substituted independently with one or more substituents selected from

[0780] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[0781] R 8 and R 9 are independently selected from

[0782] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group and 5- to 10-membered heteroaryl or

[0783] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0784] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted independently with one or more substituents selected from

[0785] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” , C(=O)-OR 10” and C(=O)NR11” R 12” ,

[0786] R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[0787] R 8’ , R 9’ , R 10’ , R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[0788] R 8” , R 9” , R 10” , R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl,

[0789] and

[0790] R 25 It is hydrogen or methyl, preferably hydrogen.

[0791] In one embodiment of the present invention and / or its embodiments,

[0792] R 7 Independently selected from

[0793] Hydrogen, C 1-6- Alkyl, C 2-6- alkenyl, 4 to 10 membered heterocyclic group, C 1-3- Alkoxy, hydroxyl, NR 8 R 9 ,

[0794] Among them C 1-6- Alkyl, C 2-6- alkenyl, 4 to 10 membered heterocyclic group or C 1-3- The alkoxy groups are each optionally substituted with one or more substituents independently selected from the following

[0795] C 1-3- Alkyl, 5- to 10-membered heterocyclic group, C 1-6- Alkoxy, halogen, cyano, hydroxyl, NR 8’ R 9’ ,

[0796] R 8 and R 9 Independently selected from

[0797] Hydrogen, C 1-6- Alkyl, C 6-10-Aryl and 5- to 10-membered heteroaryl or

[0798] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0799] wherein C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the following

[0800] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ;

[0801] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[0802] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[0803] and

[0804] R 25 is hydrogen or methyl, preferably hydrogen.

[0805] In one embodiment of the present invention and / or its embodiments,

[0806] R 7 is independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methanesulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl,

[0807] and

[0808] R 25 is hydrogen or methyl, preferably hydrogen.

[0809] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Imi) or (Imii)

[0810]

[0811] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs, and mixtures thereof, wherein R 1 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 and R 19 are defined as in any of the embodiments described herein.

[0812] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Imi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Imii), preferably in the (S)-enantiomeric form.

[0813] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 13 、R 14 、R 15 、R 16 、R 17 and R 18 as well as R 19 are defined as above.

[0814] In one embodiment of the present invention and / or its embodiments

[0815] R 13 and R 14 together with the atoms to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the non-aromatic ring is optionally substituted by one or more C 1-3- alkyl or =O, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, -S(O)-, -S(O) 2 - or -S-

[0816] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- alkyl

[0817] R16 Independently is hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” , where R 16’ and R 16” are independently C 1-3- alkyl,

[0818] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0819] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0820] And

[0821] R 19 is independently selected from

[0822] C 6-10- aryl and 5- to 10-membered heteroaryl,

[0823] wherein C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted by one or more substituents independently selected from the following: C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(=O)OR 22 and C(=O)NR 23 R 24 ,

[0824] R 20 and R 21 are independently selected from

[0825] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[0826] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0827] wherein C 1-6- alkyl, C 3-10- cycloalkyl or C6-10- An aryl or a heterocycle formed by R 20 and R 21 together with the N atom to which it is attached is each optionally substituted with one or more substituents independently selected from the following

[0828] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’

[0829] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl.

[0830] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl.

[0831] In one embodiment of the present invention and / or its embodiments,

[0832] R 13 and R 14 together with the atoms to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, and one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O- or -S-,

[0833] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0834] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0835] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0836] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[0837] and

[0838] R 19 is C 6-10- aryl,

[0839] wherein C 6-10 aryl is phenyl substituted with one, two or three substituents independently selected from: fluoride, chloride, and bromide.

[0840] In one embodiment of the present invention and / or its embodiments,

[0841] R 13 and R 14 together with the atom to which it is attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH- or -O-,

[0842] R 15 is independently hydrogen or C 1-3 alkoxy,

[0843] R 16 is independently hydrogen or C 1-3 alkoxy,

[0844] R 17 is independently hydrogen or C 1-3 alkoxy,

[0845] R 18 is independently hydrogen or C 1-3 alkoxy.

[0846] and

[0847] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl, and 3,5-dichlorophenyl.

[0848] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ini), (Inii), (Iniii), (Iniv), (Inv), (Invi), (Invii), (Inviii) or (Inix)

[0849]

[0850]

[0851]

[0852] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs, and mixtures thereof, wherein R 1 and R 7 and R 25 are as defined in any of the embodiments described herein.

[0853] In one embodiment of the invention and / or its embodiments, the compound is according to formula (Ini), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Inii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iniii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iniv), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Inv), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Invi), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Invii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Inviii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Inix), preferably in the (S)-enantiomeric form.

[0854] In one embodiment of the invention and / or its embodiments,

[0855] R 13 and R 14 together with the atoms to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally substituted by one or more C 1-3 -alkyl groups, and / or wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -N=, =N-, -O-, or -S-,

[0856] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- alkyl,

[0857] R 16 is independently hydrogen, halogen, C1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” , wherein R 16’ and R 16” are independently C 1-3- alkyl,

[0858] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0859] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0860] and

[0861] R 19 is independently selected from

[0862] C 6-10- aryl and 5- to 10-membered heteroaryl,

[0863] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted with one or more substituents independently selected from C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocycloalkyl, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(=O)OR 22 and C(=O)NR 23 R 24 ,

[0864] R 20 and R 21 are independently selected from

[0865] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[0866] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0867] wherein the C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or formed by R20 and R 21 The heterocycles formed together with the N atoms to which they are attached are each optionally substituted by one or more substituents independently selected from the following

[0868] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’

[0869] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[0870] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl.

[0871] In one embodiment of the present invention and / or its embodiments,

[0872] R 13 and R 14 together with the atoms to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[0873] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0874] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0875] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0876] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0877] and

[0878] R 19 is C 6-10- aryl,

[0879] wherein C 6-10 aryl is phenyl substituted with one, two or three substituents independently selected from: fluoride, chloride, and bromide.

[0880] In one embodiment of the present invention and / or its embodiments,

[0881] R 13 and R 14 together with the atom to which it is attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, or -S-.

[0882] R 15 is independently hydrogen or C 1-3 alkoxy,

[0883] R 16 is independently hydrogen or C 1-3 alkoxy,

[0884] R 17 is independently hydrogen or C 1-3 alkoxy,

[0885] R 18 is independently hydrogen or C 1-3 alkoxy

[0886] and

[0887] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl, and 3,5-dichlorophenyl.

[0888] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Inx), (Inxi), (Inxii), (Inxiii), (Inxiv), or (Inxv)

[0889]

[0890]

[0891]

[0892] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs, and mixtures thereof, wherein R 1 、R7 and R 25 as defined in any of the embodiments described herein.

[0893] In one embodiment of the invention and / or its embodiments, the compound is according to formula (Inx), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Inxi), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Inxii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Inxiii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Inxiv), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Inxv), preferably in the (S)-enantiomeric form.

[0894] The present invention provides a compound according to the invention and / or its embodiments, wherein R 13 , R 14 , R 15 , R 16 , R 17 and R 18 and also R 25 as defined above.

[0895] In one embodiment of the invention and / or its embodiments,

[0896] R 13 and R 14 together with the atoms to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the non-aromatic ring is optionally substituted by one or more C 1-3- alkyl or =O, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, -S(O)-, -S(O) 2 - or -S-,

[0897] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” , wherein R 15’ and R 15” are independently C 1-3- alkyl,

[0898] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C1-3 alkoxy or NR 16’ R 16” , wherein R 16’ and R 16” are independently C 1-3- alkyl,

[0899] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0900] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0901] and

[0902] R 25 is hydrogen or methyl, preferably hydrogen.

[0903] In one embodiment of the present invention and / or its embodiments,

[0904] R 13 and R 14 together with the atoms to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O- or -S-,

[0905] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0906] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0907] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0908] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0909] and

[0910] R 25 is hydrogen or methyl, preferably hydrogen.

[0911] In one embodiment of the present invention and / or its embodiments,

[0912] R 13 and R 14Together with the atom to which it is attached, form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH- or -O-.

[0913] R 15 is independently hydrogen or C 1-3 alkoxy

[0914] R 16 is independently hydrogen or C 1-3 alkoxy

[0915] R 17 is independently hydrogen or C 1-3 alkoxy

[0916] R 18 is independently hydrogen or C 1-3 alkoxy

[0917] and

[0918] R 25 is hydrogen or methyl, preferably hydrogen.

[0919] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ioi), (Ioii) or (Ioiii)

[0920]

[0921] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 1 、R 7 and R 19 are defined as in any of the embodiments described herein.

[0922] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ioi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ioii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ioiii), preferably in the (S)-enantiomeric form.

[0923] In one embodiment of the present invention and / or its embodiments,

[0924] R 13 and R 14 together with the atom to which they are attached, form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally substituted by one or more C 1-3-alkyl-substituted, and / or one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[0925] R 15 independently is hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” , where R 15’ and R 15” independently is C 1-3- alkyl,

[0926] R 16 independently is hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” , where R 16’ and R 16” independently is C 1-3- alkyl,

[0927] R 17 independently is hydrogen, C 1-3 alkyl or C 1-3 ,

[0928] R 18 independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0929] and

[0930] R 25 is hydrogen or methyl, preferably hydrogen.

[0931] In one embodiment of the present invention and / or its embodiments,

[0932] R 13 and R 14 together with the atoms to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, where one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[0933] R 15 independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0934] R 16 independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[0935] R 17 independently is hydrogen, C1-3 alkyl or C 1-3 alkoxy,

[0936] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[0937] and

[0938] R 25 is hydrogen or methyl, preferably hydrogen.

[0939] In one embodiment of the present invention and / or its embodiments,

[0940] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N- or -S-,

[0941] R 15 is independently hydrogen or C 1-3 alkoxy,

[0942] R 16 is independently hydrogen or C 1-3 alkoxy,

[0943] R 17 is independently hydrogen or C 1-3 alkoxy,

[0944] R 18 is independently hydrogen or C 1-3 alkoxy.

[0945] and

[0946] R 25 is hydrogen or methyl, preferably hydrogen.

[0947] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ioiv) or (Iov)

[0948]

[0949] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 1 , R 7 and R 19 are defined as in any of the embodiments described herein.

[0950] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iovi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iov), preferably in the (S)-enantiomeric form.

[0951] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 19 and R 25 are as defined above.

[0952] In one embodiment of the present invention and / or its embodiments,

[0953] R 19 is independently selected from

[0954] C 6-10- aryl and 5- to 10-membered heteroaryl,

[0955] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted with one or more substituents independently selected from the following

[0956] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(=O)OR 22 and C(=O)NR 23 R 24 .

[0957] R 20 and R 21 are independently selected from

[0958] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[0959] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[0960] wherein the C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or formed by R 20 and R 21The heterocycles formed together with the N atoms to which they are attached are each optionally substituted by one or more substituents independently selected from the following

[0961] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’ ,

[0962] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[0963] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl,

[0964] and

[0965] R 25 is hydrogen or methyl, preferably hydrogen.

[0966] In one embodiment of the present invention and / or its embodiments,

[0967] R 19 is C 6-10- aryl,

[0968] wherein the C 6-10 aryl is a phenyl group substituted by one, two or three substituents independently selected from: fluoride, chloride and bromide,

[0969] and

[0970] R 25 is hydrogen or methyl, preferably hydrogen.

[0971] In one embodiment of the present invention and / or its embodiments,

[0972] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl,

[0973] and

[0974] R 25 is hydrogen or methyl, preferably hydrogen.

[0975] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ipi), (Ipii) or (Ipiii)

[0976]

[0977] or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug thereof and mixtures thereof, wherein R 1 , R 7 and R 13 , R 14 , R 15 , R 16 , R 17 and R 18 are defined as in any of the embodiments described herein.

[0978] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ipi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ipii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ipiii), preferably in the (S)-enantiomeric form.

[0979] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 1 , R 7 and R 13 , R 14 , R 15 , R 16 , R 17 and R 18 are as defined above.

[0980] In one embodiment of the present invention and / or its embodiments,

[0981] R 1 is independently selected from

[0982] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(=O)OR 4 and C(=O)NR 5 R 6 ,

[0983] wherein C 1-6-An alkyl group or C 1-6- The alkoxy group is each optionally substituted independently by one or more substituents selected from the following

[0984] C 1-6- alkyl group, C 1-6- alkoxy group, halogen, cyano group, nitro group, hydroxyl group, and NR 2’ R 3’ ,

[0985] R 2 and R 3 are independently selected from

[0986] hydrogen, C 1-6- alkyl group, C 3-10- cycloalkyl group, C 6-10- aryl group, and 5- to 10-membered heteroaryl group, or R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O.

[0987] wherein C 1-6- alkyl group, C 3-10- cycloalkyl group, C 6-10- aryl group, 5- to 10-membered heteroaryl group, or the heterocycle formed by R 2 and R 3 together with the N atom to which they are attached is each optionally substituted independently by one or more substituents selected from the following

[0988] C 1-6- alkyl group, C 3-10- cycloalkyl group, and C 1-6- alkoxy group.

[0989] R 4 , R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl group, preferably selected from hydrogen and C 1-3- alkyl group.

[0990] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl group, preferably selected from hydrogen and C 1-3- alkyl group.

[0991] and

[0992] R 7 is independently selected from

[0993] hydrogen, C 1-6- alkyl group, C 2-6- alkenyl group, C 3-10-Cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 , C(=O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(=O)NR 11 R 12 ,

[0994] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally independently substituted with one or more substituents selected from

[0995] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[0996] R 8 and R 9 are independently selected from

[0997] hydrogen, C 1-6 -alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group and 5- to 10-membered heteroaryl or

[0998] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[0999] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally independently substituted with one or more substituents selected from

[1000] C 1-6- alkyl, C1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” , C(=O)OR 10” and C(=O)NR 11” R 12”

[1001] R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[1002] R 8’ , R 9’ , R 10’ , R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[1003] R 8” , R 9” , R 10” , R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl,

[1004] and

[1005] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the non-aromatic ring is optionally substituted by one or more C1-3-alkyl or =O, and / or wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -O-, -S(O)-, -S(O)2- or -S-,

[1006] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” , wherein R 15’ and R 15” are independently C 1-3- alkyl,

[1007] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” , wherein R 16’ and R 16” are independently C 1-3- alkyl,

[1008] R17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1009] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[1010] Optionally, in one embodiment of the present invention and / or its embodiments,

[1011] R 1 is independently selected from

[1012] hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen,

[1013] wherein the C 1-6- alkyl and C 1-6- alkoxy are optionally substituted with one or more substituents independently selected from the following

[1014] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[1015] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably from hydrogen and methyl,

[1016] and

[1017] R 7 is independently selected from

[1018] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group, C 1-3- alkoxy, hydroxy, NR 8 R 9 ,

[1019] wherein each C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group or C 1-3- alkoxy is optionally substituted with one or more substituents independently selected from the following

[1020] C 1-3- alkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ ,

[1021] R 8 and R 9 are independently selected from

[1022] hydrogen, C 1-6- alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[1023] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[1024] wherein C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted by one or more substituents independently selected from the following

[1025] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ;

[1026] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1027] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1028] and

[1029] R 13 and R 14 together with the atoms to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O- or -S-,

[1030] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1031] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1032] R 17Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1033] R 18 Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[1034] In one embodiment of the present invention and / or its embodiments,

[1035] R 1 Independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride, and chloride,

[1036] and

[1037] R 7 Independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methanesulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl, and 3,3-difluoroazetidinyl,

[1038] and

[1039] R 13 and R 14 Together with the atom to which it is attached, form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH- or -O-,

[1040] R 15 Independently is hydrogen or C 1-3 alkoxy,

[1041] R 16 Independently is hydrogen or C 1-3 alkoxy,

[1042] R 17 Independently is hydrogen or C 1-3 alkoxy,

[1043] R 18 Independently is hydrogen or C 1-3 alkoxy.

[1044] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iqi), (Iqii), (Iqiii), (Iqiv), (Iqv) or (Iqvi)

[1045]

[1046]

[1047] or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug, and mixtures thereof, wherein R 19 and R 25 are as defined in any of the embodiments described herein.

[1048] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iqi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iqii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iqiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iqiv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iqv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iqvi), preferably in the (S)-enantiomeric form.

[1049] In one embodiment of the present invention and / or its embodiments,

[1050] R 1 is independently selected from

[1051] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(=O)OR 4 and C(=O)NR 5 R 6 ,

[1052] wherein the C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[1053] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[1054] R 2 and R 3 are independently selected from

[1055] Hydrogen, C 1-6- Alkyl, C 3-10- Cycloalkyl, C 6-10- Aryl and 5 - to 10 - membered heteroaryl or

[1056] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1057] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl or 5 - to 10 - membered heteroaryl or the heterocycle formed by R 2 and R 3 together with the N atom to which they are attached is each optionally substituted by one or more substituents independently selected from

[1058] C 1-6- alkyl, C 3-10- cycloalkyl and C 1-6- alkoxy,

[1059] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1060] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1061] and

[1062] R 7 is independently selected from

[1063] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4 - to 10 - membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 、C(=O)OR 10 、SR 10 、SOR 10 、SO 2 R 10 and C(=O)NR 11 R 12 ,

[1064] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, a 4- to 10-membered heterocyclic group, or C 1-6- alkoxy is each optionally substituted independently with one or more substituents selected from

[1065] C 1-6- alkyl, C 3-10- cycloalkyl, a 5- to 10-membered heterocyclic group, C1-6-alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[1066] R 8 and R 9 are independently selected from

[1067] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, a 5- to 10-membered heterocyclic group, and a 5- to 10-membered heteroaryl, or

[1068] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O,

[1069] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, a 5- to 10-membered heterocyclic group, or a 5- to 10-membered heteroaryl, or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted independently with one or more substituents selected from

[1070] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” , C(=O)OR 10” and C(=O)NR 11” R 12”

[1071] R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[1072] R 8’ , R 9’ , R 10’ , R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[1073] R 8” , R 9” , R 10” , R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl,

[1074] and

[1075] R 13 and R 14 Together with the atoms to which they are attached, they form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally replaced by one or more C 1-3- alkyl, and / or one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[1076] R 15 are independently hydrogen, halogen, C 1-3 Alkyl, C 1-3 Alkoxy or NR 15’ R 15” , where R 15’ and R 15” Independently C 1-3- alkyl,

[1077] R 16 are independently hydrogen, halogen, C 1-3 Alkyl, C 1-3 Alkoxy or NR 16’ R 16” , where R 16’ and R 16” Independently C 1-3- alkyl,

[1078] R 17 are independently hydrogen, C 1-3 Alkyl or C 1-3 Alkoxy,

[1079] R 18 are independently hydrogen, C 1-3 Alkyl or C 1-3 Alkoxy.

[1080] Optionally, in one embodiment of the present invention and / or its embodiments,

[1081] R1 independently selected from

[1082] hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen,

[1083] wherein C 1-6- alkyl and C 1-6- alkoxy are optionally substituted with one or more substituents independently selected from

[1084] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[1085] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl,

[1086] and

[1087] R 7 is independently selected from

[1088] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group, C 1-3- alkoxy, hydroxy, NR 8 R 9 ,

[1089] wherein C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group or C 1-3- alkoxy are each optionally substituted with one or more substituents independently selected from

[1090] C 1-3- alkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ ,

[1091] R 8 and R 9 are independently selected from

[1092] hydrogen, C 1-6- alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[1093] R 8 and R 9Together with the N atom to which it is attached, form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[1094] wherein C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which it is attached is optionally substituted with one or more substituents independently selected from

[1095] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ;

[1096] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1097] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1098] and

[1099] R 13 and R 14 together with the atom to which it is attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-

[1100] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1101] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1102] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1103] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[1104] In one embodiment of the present invention and / or its embodiments,

[1105] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride, and chloride,

[1106] and

[1107] R 7 is independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methanesulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl, and 3,3-difluoroazetidinyl,

[1108] and

[1109] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, or -S-,

[1110] R 15 is independently hydrogen or C 1-3 alkoxy,

[1111] R 16 is independently hydrogen or C 1-3 alkoxy,

[1112] R 17 is independently hydrogen or C 1-3 alkoxy,

[1113] R 18 is independently hydrogen or C 1-3 alkoxy.

[1114] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iqvii), (Iqviii), (Iqix) or (Iqx)

[1115]

[1116]

[1117] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs, and mixtures thereof, wherein R 19 and R 25 are defined as in any of the embodiments described herein.

[1118] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iqvii), preferably in the form of the (S)-enantiomer. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iqviii), preferably in the form of the (S)-enantiomer. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iqix), preferably in the form of the (S)-enantiomer. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iqx), preferably in the form of the (S)-enantiomer.

[1119] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 1 、R 7 and R 19 are as defined above.

[1120] In one embodiment of the present invention and / or its embodiments,

[1121] R 1 is independently selected from

[1122] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 、C(=O)OR 4 and C(=O)NR 5 R 6 ,

[1123] wherein C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from

[1124] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[1125] R 2 and R 3 are independently selected from

[1126] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[1127] R 2 and R 3Together with the N atom to which it is attached, form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 1 ring atom is N and 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[1128] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 2 and R 3 together with the N atom to which it is attached is each optionally substituted by one or more substituents independently selected from the following

[1129] C 1-6- alkyl, C 3-10- cycloalkyl and C 1-6- alkoxy,

[1130] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1131] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1132] and

[1133] R 7 is independently selected from the following

[1134] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 、C(=O)OR 10 、SR 10 、SOR 10 、SO 2 R 10 and C(=O)NR 11 R 12 ,

[1135] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally substituted by one or more substituents independently selected from the following

[1136] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[1137] R 8 and R 9 are independently selected from

[1138] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group and 5- to 10-membered heteroaryl or

[1139] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[1140] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted by one or more substituents independently selected from the following

[1141] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” , C(=O)OR 10” and C(=O)NR 11” R 12”

[1142] R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[1143] R 8’ , R 9’ , R 10’ , R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[1144] R 8” 、R 9” 、R 10” 、R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl

[1145] and

[1146] R 19 is independently selected from

[1147] C 6-10- aryl and 5- to 10-membered heteroaryl

[1148] wherein each C 6-10- aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more substituents independently selected from the following

[1149] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 、C(=O)OR 22 and C(=O)NR 23 R 24 ,

[1150] R 20 and R 21 are independently selected from

[1151] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[1152] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[1153] wherein C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the following

[1154] C 1-6- alkyl, C 3-10- cycloalkyl, C1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’

[1155] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[1156] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl.

[1157] Optionally, in one embodiment of the present invention and / or its embodiments,

[1158] R 1 is independently selected from

[1159] hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen,

[1160] wherein C 1-6- alkyl and C 1-6- alkoxy are optionally substituted by one or more substituents independently selected from the following

[1161] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[1162] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl,

[1163] and

[1164] R 7 is independently selected from

[1165] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group, C 1-3- alkoxy, hydroxy, NR 8 R 9 ,

[1166] wherein C 1-6- alkyl, C 2-6- alkenyl, a 4- to 10-membered heterocyclic group or C 1-3- alkoxy is each optionally substituted by one or more substituents independently selected from the following

[1167] C 1-3- alkyl, a 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ ,

[1168] R 8 and R 9 are independently selected from

[1169] hydrogen, C 1-6- alkyl, C 6-10- aryl and a 5- to 10-membered heteroaryl or

[1170] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1171] wherein C 1-6- alkyl, C 6-10- aryl or a 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted by one or more substituents independently selected from the following

[1172] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ;

[1173] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1174] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1175] and

[1176] R 19 is C 6-10- aryl,

[1177] wherein C6-10 An aryl is a phenyl substituted by one, two or three substituents independently selected from fluoride, chloride and bromide.

[1178] In one embodiment of the present invention and / or its embodiments,

[1179] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride,

[1180] and

[1181] R 7 is independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methanesulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl,

[1182] and

[1183] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl.

[1184] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iri), (Irii), (Iriii), (Iriv), (Irv) or (Irvi)

[1185]

[1186]

[1187]

[1188] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 13 、R 14 、R 15 、R 16 、R 17 and R 18 and R 25 are as defined in any of the embodiments described herein.

[1189] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iri), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Irii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iriii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iriv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Irv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Irvi), preferably in the (S)-enantiomeric form.

[1190] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 1 , R 7 and R 25 are as defined above.

[1191] In one embodiment of the present invention and / or its embodiments,

[1192] R 1 is independently selected from

[1193] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(=O)OR 4 and C(=O)NR 5 R 6 ,

[1194] wherein C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from

[1195] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[1196] R 2 and R 3 are independently selected from

[1197] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[1198] R 2 and R 3 together with the N atom to which it is attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1199] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 2 and R 3 together with the N atom to which it is attached is each optionally substituted with one or more substituents independently selected from the following

[1200] C 1-6- alkyl, C 3-10- cycloalkyl and C 1-6- alkoxy,

[1201] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1202] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1203] and

[1204] R 7 is independently selected from

[1205] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 、C(=O)OR 10 、SR 10 、SOR 10 、SO 2 R 10 and C(=O)NR 11 R 12 ,

[1206] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10-Cycloalkyl, 4- to 10-membered heterocyclic group, or C 1-6- alkoxy is each optionally independently substituted with one or more substituents selected from the following

[1207] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[1208] R 8 and R 9 are independently selected from

[1209] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, and 5- to 10-membered heteroaryl, or

[1210] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O

[1211] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, or 5- to 10-membered heteroaryl, or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally independently substituted with one or more substituents selected from the following

[1212] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” , C(=O)OR 10” and C(=O)NR 11” R 12” ,

[1213] R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[1214] R 8’ , R 9’ , R 10’, R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl

[1215] R 8” , R 9” , R 10” , R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl

[1216] and

[1217] R 25 is hydrogen or methyl, preferably hydrogen

[1218] Optionally, in one embodiment of the present invention and / or its embodiments

[1219] R 1 is independently selected from

[1220] hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen

[1221] wherein the C 1-6- alkyl and C 1-6- alkoxy are optionally substituted with one or more substituents independently selected from

[1222] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[1223] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl

[1224] and

[1225] R 7 is independently selected from

[1226] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group, C 1-3- alkoxy, hydroxy, NR 8 R 9 ,

[1227] wherein each C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group or C 1-3- alkoxy is optionally substituted with one or more substituents independently selected from

[1228] C 1-3- alkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ ,

[1229] R 8 and R 9 are independently selected from

[1230] hydrogen, C 1-6- alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[1231] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1232] wherein C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from

[1233] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ,

[1234] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1235] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1236] and

[1237] R 25 is hydrogen or methyl, preferably hydrogen.

[1238] In one embodiment of the present invention and / or its embodiments,

[1239] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride,

[1240] and

[1241] R 7 independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, mesyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl,

[1242] and

[1243] R 25 is hydrogen or methyl, preferably hydrogen.

[1244] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Isi) or (Isii)

[1245]

[1246] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 13 、R 14 、R 15 、R 16 、R 17 and R 18 and R 19 are defined as in any of the embodiments described herein.

[1247] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Isi), preferably in the form of the (S)-enantiomer. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Isii), preferably in the form of the (S)-enantiomer.

[1248] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 1 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 and R 19 are as defined above.

[1249] In one embodiment of the present invention and / or its embodiments,

[1250] R 1 is independently selected from

[1251] hydrogen, C 1-6-Alkyl, C 1-6- Alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(=O)OR 4 And C(=O)NR 5 R 6 ,

[1252] Wherein C 1-6- Alkyl or C 1-6- Alkoxy is each optionally substituted independently by one or more substituents selected from the following

[1253] C 1-6- Alkyl, C 1-6- Alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[1254] R 2 And R 3 Are independently selected from

[1255] Hydrogen, C 1-6- Alkyl, C 3-10- Cycloalkyl, C 6-10- Aryl and 5- to 10-membered heteroaryl or

[1256] R 2 And R 3 Together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1257] Wherein C 1-6- Alkyl, C 3-10- Cycloalkyl, C 6-10- Aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 2 And R 3 Together with the N atom to which they are attached is each optionally substituted independently by one or more substituents selected from the following

[1258] C 1-6- Alkyl, C 3-10- Cycloalkyl and C 1-6- Alkoxy,

[1259] R 4 , R 5 And R 6 Are independently selected from hydrogen and C 1-6- Alkyl, preferably selected from hydrogen and C 1-3- Alkyl,

[1260] R 2’ And R 3’ Are independently selected from hydrogen and C1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1261] and

[1262] R 13 and R 14 together with the atom to which it is attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the non-aromatic ring is optionally substituted by one or more C 1-3- alkyl or =O, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, -S(O)-, -S(O) 2 - or -S-,

[1263] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- alkyl,

[1264] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” are independently C 1-3- alkyl,

[1265] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1266] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1267] and

[1268] R 19 is independently selected from

[1269] C 6-10- aryl and 5- to 10-membered heteroaryl,

[1270] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted by one or more substituents independently selected from the following

[1271] C 1-6- alkyl, C 3-10-Naphthenyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(=O)OR 22 and C(=O)NR 23 R 24 ,

[1272] R 20 and R 21 are independently selected from

[1273] hydrogen, C 1-6- alkyl, C 3-10- naphthenyl and C 6-10- aryl or

[1274] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1275] wherein C 1-6- alkyl, C 3-10- naphthenyl or C 6-10- aryl or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is each optionally substituted independently by one or more substituents selected from the following

[1276] C 1-6- alkyl, C 3-10- naphthenyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’ ,

[1277] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[1278] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl.

[1279] Optionally, in one embodiment of the present invention and / or its embodiments,

[1280] R 1 is independently selected from

[1281] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, and halogen,

[1282] wherein C 1-6- alkyl and C 1-6- alkoxy are optionally substituted with one or more substituents independently selected from the following

[1283] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, and NR 2’ R 3’ ,

[1284] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl,

[1285] and

[1286] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, or -S-,

[1287] R 15 is independently hydrogen, C 1-3 alkyl, or C 1-3 alkoxy,

[1288] R 16 is independently hydrogen, C 1-3 alkyl, or C 1-3 alkoxy,

[1289] R 17 is independently hydrogen, C 1-3 alkyl, or C 1-3 alkoxy,

[1290] R 18 is independently hydrogen, C 1-3 alkyl, or C 1-3 alkoxy,

[1291] and

[1292] R 19 is C 6-10- aryl,

[1293] wherein C6-10 An aryl is a phenyl group substituted with one, two or three substituents independently selected from fluoride, chloride and bromide.

[1294] In one embodiment of the present invention and / or its embodiments,

[1295] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride,

[1296] and

[1297] R 13 and R 14 together with the atom to which it is attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH- or -O-,

[1298] R 15 is independently hydrogen or C 1-3 alkoxy,

[1299] R 16 is independently hydrogen or C 1-3 alkoxy,

[1300] R 17 is independently hydrogen or C 1-3 alkoxy,

[1301] R 18 is independently hydrogen or C 1-3 alkoxy,

[1302] and

[1303] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl.

[1304] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iti), (Itii), (Itiii), (Itiv), (Itv), (Itvi), (Itvii), (Itviii) or (Itix)

[1305]

[1306]

[1307]

[1308] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R7 and R 25 as defined in any of the embodiments described herein.

[1309] In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iti), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Itii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Itiii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Itiv), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Itv), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Itvi), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Itvii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Itviii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Itix), preferably in the (S)-enantiomeric form.

[1310] In one embodiment of the invention and / or its embodiments,

[1311] R 1 is independently selected from

[1312] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 、C(=O)OR 4 and C(=O)NR 5 R 6 ,

[1313] wherein C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[1314] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[1315] R 2and R 3 are independently selected from

[1316] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, and 5- to 10-membered heteroaryl or

[1317] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O,

[1318] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, or 5- to 10-membered heteroaryl or the heterocycle formed by R 2 and R 3 together with the N atom to which they are attached are each optionally substituted independently with one or more substituents selected from C 1-6- alkyl, C 3-10- cycloalkyl, and C 1-6- alkoxy,

[1319] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1320] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1321] and

[1322] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally substituted with one or more C 1-3- alkyl, and / or wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -N=, =N-, -O-, or -S-,

[1323] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 15’ R 15” wherein R 15’ and R 15” are independently C1-3- alkyl

[1324] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” are independently C 1-3- alkyl

[1325] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1326] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1327] and

[1328] R 19 is independently selected from

[1329] C 6-10- aryl and 5- to 10-membered heteroaryl

[1330] wherein each C 6-10- aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more substituents independently selected from the following

[1331] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 、C(=O)OR 22 and C(=O)NR 23 R 24 ,

[1332] R 20 and R 21 are independently selected from

[1333] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[1334] R 20 and R 21Together with the N atom to which it is attached, form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1335] wherein C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or the heterocycle formed by R 20 and R 21 together with the N atom to which it is attached is each optionally substituted by one or more substituents independently selected from the following

[1336] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ 、C(=O)OR 22’ and C(=O)NR 23’ R 24’ ,

[1337] R 22 、R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[1338] R 20’ 、R 21’ 、R 22’ 、R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl.

[1339] Optionally, in one embodiment of the present invention and / or its embodiments,

[1340] R 1 is independently selected from

[1341] hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen,

[1342] wherein C 1-6- alkyl and C 1-6- alkoxy are each optionally substituted by one or more substituents independently selected from the following

[1343] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[1344] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl,

[1345] and

[1346] R 13 and R 14 together with the atom to which it is attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-

[1347] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1348] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1349] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1350] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1351] and

[1352] R 19 is C 6-10- aryl,

[1353] wherein C 6-10 aryl is a phenyl group substituted by one, two or three substituents independently selected from: fluoride, chloride and bromide.

[1354] In one embodiment of the present invention and / or its embodiments,

[1355] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride,

[1356] and

[1357] R 13 and R 14 together with the atom to which it is attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N- or -S-

[1358] R 15 is independently hydrogen or C 1-3 alkoxy,

[1359] R 16 is independently hydrogen or C 1-3 alkoxy,

[1360] R 17 is independently hydrogen or C 1-3 alkoxy,

[1361] R 18 is independently hydrogen or C 1-3 alkoxy.

[1362] and

[1363] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl.

[1364] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Itx), (Itxi), (Itxii), (Itxiii), (Itxiv) or (Itxv)

[1365]

[1366]

[1367]

[1368] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 7 and R 25 are defined as in any of the embodiments described herein.

[1369] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Itx), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Itxi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Itxii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Itxiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ixitv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Itxv), preferably in the (S)-enantiomeric form.

[1370] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 1 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 25 are as defined above.

[1371] In one embodiment of the present invention and / or its embodiments,

[1372] R 1 is independently selected from

[1373] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(=O)OR 4 and C(=O)NR 5 R 6 ,

[1374] wherein the C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[1375] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[1376] R 2 and R 3 are independently selected from

[1377] Hydrogen, C 1-6- Alkyl, C 3-10- Cycloalkyl, C 6-10- Aryl and 5- to 10-membered heteroaryl or

[1378] R 2 and R 3 together with the N atom to which it is attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1379] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or a heterocycle formed by R 2 and R 3 together with the N atom to which it is attached are each optionally substituted independently by one or more substituents selected from the following

[1380] C 1-6- alkyl, C 3-10- cycloalkyl and C 1-6- alkoxy,

[1381] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1382] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1383] and

[1384] R 13 and R 14 together with the atom to which it is attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the non-aromatic ring is optionally substituted by one or more C 1-3- alkyl or =O, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, -S(O)-, -S(O) 2 - or -S-,

[1385] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” wherein R 15’ and R15” is independently C 1-3- alkyl

[1386] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” are independently C 1-3- alkyl

[1387] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1388] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1389] and

[1390] R 25 is hydrogen or methyl, preferably hydrogen

[1391] Optionally, in one embodiment of the present invention and / or its embodiments

[1392] R 1 is independently selected from

[1393] hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen

[1394] wherein C 1-6- alkyl and C 1-6- alkoxy are optionally substituted with one or more substituents independently selected from the following

[1395] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[1396] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl

[1397] and

[1398] R 13 and R 14Together with the atom to which it is attached, form a non-aromatic ring containing 5 or 6 carbon atoms, where one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O- or -S-.

[1399] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[1400] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[1401] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

[1402] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1403] and

[1404] R 25 is hydrogen or methyl, preferably hydrogen.

[1405] In one embodiment of the present invention and / or its embodiments,

[1406] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride,

[1407] and

[1408] R 13 and R 14 together with the atom to which they are attached, form a non-aromatic ring containing 5 or 6 carbon atoms, where one or more of the carbon atoms forming the ring are optionally replaced by -NH- or -O-.

[1409] R 15 is independently hydrogen or C 1-3 alkoxy,

[1410] R 16 is independently hydrogen or C 1-3 alkoxy,

[1411] R 17 is independently hydrogen or C 1-3 alkoxy,

[1412] R 18 is independently hydrogen or C 1-3 alkoxy,

[1413] and

[1414] R 25 is hydrogen or methyl, preferably hydrogen.

[1415] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iui), (Iuii) or (Iuiii)

[1416]

[1417] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 7 and R 19 are defined as in any of the embodiments described herein.

[1418] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iui), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iuii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iuiii), preferably in the (S)-enantiomeric form.

[1419] In one embodiment of the present invention and / or its embodiments,

[1420] R 1 is independently selected from

[1421] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(=O)OR 4 and C(=O)NR 5 R 6 ,

[1422] wherein C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted independently by one or more substituents selected from the following

[1423] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[1424] R 2 and R 3 are independently selected from

[1425] hydrogen, C 1-6- alkyl, C3-10- Cycloalkyl, C 6-10- aryl, and 5- to 10-membered heteroaryl, or

[1426] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O,

[1427] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, or 5- to 10-membered heteroaryl, or the heterocycle formed by R 2 and R 3 together with the N atom to which they are attached are each optionally substituted with one or more substituents independently selected from the following

[1428] C 1-6- alkyl, C 3-10- cycloalkyl, and C 1-6- alkoxy,

[1429] R 4 , R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1430] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1431] and

[1432] R 13 and R 14 together with the atoms to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally substituted with one or more C 1-3- alkyl, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O-, or -S-,

[1433] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- alkyl,

[1434] R16 independently is hydrogen, a halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” independently is C 1-3- alkyl,

[1435] R 17 independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1436] R 18 independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1437] and

[1438] R 25 is hydrogen or methyl, preferably hydrogen.

[1439] Optionally, in one embodiment of the present invention and / or its embodiments,

[1440] R 1 independently is selected from

[1441] hydrogen, C 1-6- alkyl, C 1-6- alkoxy and halogen,

[1442] wherein C 1-6- alkyl and C 1-6- alkoxy are optionally substituted with one or more substituents independently selected from the following

[1443] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[1444] R 2’ and R 3’ independently are selected from hydrogen and C 1-3- alkyl, more preferably selected from hydrogen and methyl,

[1445] and

[1446] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[1447] R 15Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1448] R 16 Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1449] R 17 Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1450] R 18 Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1451] and

[1452] R 25 is hydrogen or methyl, preferably hydrogen.

[1453] In one embodiment of the present invention and / or its embodiments,

[1454] R 1 is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride, and chloride,

[1455] and

[1456] R 13 and R 14 together with the atom to which it is attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, or -S-,

[1457] R 15 is independently hydrogen or C 1-3 alkoxy,

[1458] R 16 is independently hydrogen or C 1-3 alkoxy,

[1459] R 17 is independently hydrogen or C 1-3 alkoxy,

[1460] R 18 is independently hydrogen or C 1-3 alkoxy.

[1461] and

[1462] R 25 is hydrogen or methyl, preferably hydrogen.

[1463] In one embodiment of the present invention and / or its embodiments, the compound is as shown in formula (Iuiv) or (Iuv)

[1464]

[1465] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 7 and R 19 are defined as in any of the embodiments described herein.

[1466] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iuiv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iuv), preferably in the (S)-enantiomeric form.

[1467] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 1 、R 19 and R 25 are as defined above.

[1468] In one embodiment of the present invention and / or its embodiments

[1469] R 1 is independently selected from

[1470] hydrogen, C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 、C(=O)OR 4 and C(=O)NR 5 R 6 ,

[1471] wherein C 1-6- alkyl or C 1-6- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[1472] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, nitro, hydroxy and NR 2’ R 3’ ,

[1473] R 2 and R 3 are independently selected from

[1474] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10-Aryl and 5- to 10-membered heteroaryl or

[1475] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1476] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 2 and R 3 together with the N atom to which they are attached is each optionally substituted with one or more substituents independently selected from the following

[1477] C 1-6- alkyl, C 3-10- cycloalkyl and C 1-6- alkoxy,

[1478] R 4 、R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1479] R 2’ and R 3’ are independently selected from hydrogen and C 1-6- alkyl, preferably selected from hydrogen and C 1-3- alkyl,

[1480] and

[1481] R 19 is independently selected from

[1482] C 6-10- aryl and 5- to 10-membered heteroaryl,

[1483] wherein C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted with one or more substituents independently selected from the following

[1484] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 、C(=O)OR 22 and C(=O)NR 23 R 24,

[1485] R 20 and R 21 are independently selected from

[1486] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[1487] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1488] wherein C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is each optionally substituted by one or more substituents independently selected from

[1489] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’ ,

[1490] R 22 、R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[1491] R 20’ 、R 21’ 、R 22’ 、R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl

[1492] and

[1493] R 25 is hydrogen or methyl, preferably hydrogen.

[1494] Optionally, in one embodiment of the present invention and / or its embodiments,

[1495] R 1 is independently selected from

[1496] Hydrogen, C 1-6- Alkyl, C 1-6- Alkoxy and halogen,

[1497] wherein C 1-6- Alkyl and C 1-6- Alkoxy are optionally independently substituted by one or more substituents selected from the following

[1498] C 1-6- Alkyl, C 1-6- Alkoxy, halogen, cyano, hydroxy and NR 2’ R 3’ ,

[1499] R 2’ and R 3’ are independently selected from hydrogen and C 1-3- Alkyl, more preferably selected from hydrogen and methyl,

[1500] and

[1501] R 19 is C 6-10- Aryl,

[1502] wherein C 6-10 Aryl is a phenyl substituted by one, two or three substituents independently selected from: fluoride, chloride and bromide.

[1503] and

[1504] R 25 is hydrogen or methyl, preferably hydrogen.

[1505] In one embodiment of the present invention and / or its embodiments,

[1506] R 1 are independently selected from: hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride,

[1507] and

[1508] R 19 are independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl.

[1509] and

[1510] R 25 is hydrogen or methyl, preferably hydrogen.

[1511] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ivi), (Ivii) or (Iviii)

[1512]

[1513] or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug, and mixtures thereof, wherein R 7 、R 13 、R 14 、R 15 、R 16 、R 17 and R 18 are as defined in any of the embodiments described herein.

[1514] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ivi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ivii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iviii), preferably in the (S)-enantiomeric form.

[1515] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 7 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 and R 19 are as defined above.

[1516] In one embodiment of the present invention and / or its embodiments,

[1517] R 7 is independently selected from

[1518] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 、C(=O)OR 10 、SR 10 、SOR 10 、SO 2 R 10 and C(=O)NR 11 R 12 ,

[1519] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10-A cycloalkyl group, a 4- to 10-membered heterocyclic group, or a C 1-6- alkoxy group is each optionally independently substituted with one or more substituents selected from the following

[1520] C 1-6- alkyl group, a C 3-10- cycloalkyl group, a 5- to 10-membered heterocyclic group, a C 1-6- alkoxy group, a halogen, a cyano group, a hydroxyl group, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[1521] R 8 and R 9 are independently selected from

[1522] hydrogen, a C 1-6- alkyl group, a C 3-10- cycloalkyl group, a C 6-10- aryl group, a 5- to 10-membered heterocyclic group, and a 5- to 10-membered heteroaryl group, or

[1523] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O,

[1524] wherein the C 1-6- alkyl group, the C 3-10- cycloalkyl group, the C 6-10- aryl group, the 5- to 10-membered heterocyclic group, or the 5- to 10-membered heteroaryl group, or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally independently substituted with one or more substituents selected from the following

[1525] C 1-6- alkyl group, a C 1-6- alkoxy group, a halogen, a cyano group, a hydroxyl group, NR 8” R 9” , C(=O)OR 10” and C(=O)NR 11” R 12” ,

[1526] R 10 , R 11 , and R 12 are independently selected from hydrogen and C 1-6- alkyl group,

[1527] R 8’ , R 9’ , R 10’, R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl

[1528] R 8” , R 9” , R 10” , R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl

[1529] and

[1530] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the non-aromatic ring is optionally substituted by one or more C 1-3- alkyl or =O, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, -S(O)-, -S(O) 2 - or -S-

[1531] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” , wherein R 15’ and R 15” are independently C 1-3- alkyl

[1532] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” , wherein R 16’ and R 16” are independently C 1-3- alkyl

[1533] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1534] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1535] and

[1536] R 19 is independently selected from

[1537] C 6-10-Aryl and 5- to 10-membered heteroaryl,

[1538] wherein C 6-10- each aryl or 5- to 10-membered heteroaryl is optionally substituted independently with one or more substituents selected from the following

[1539] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(=O)OR 22 and C(=O)NR 23 R 24 ,

[1540] R 20 and R 21 are independently selected from

[1541] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[1542] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1543] wherein C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted independently with one or more substituents selected from the following

[1544] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’ ,

[1545] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6-Alkyl

[1546] R 20’ 、R 21’ 、R 22’ 、R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl

[1547] In one embodiment of the present invention and / or its embodiments

[1548] R 7 is independently selected from

[1549] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group, C 1-3- alkoxy, hydroxy, NR 8 R 9 ,

[1550] wherein C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group or C 1-3- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[1551] C 1-3- alkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ ,

[1552] R 8 and R 9 are independently selected from

[1553] hydrogen, C 1-6- alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[1554] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O

[1555] wherein C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the following

[1556] C 1-6- alkyl, C1-6- Alkoxy, hydroxy, and NR 8” R 9” ,

[1557] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl, or ethyl,

[1558] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl, or ethyl,

[1559] and

[1560] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, or -S-,

[1561] R 15 is independently hydrogen, C 1-3 alkyl, or C 1-3 alkoxy,

[1562] R 16 is independently hydrogen, C 1-3 alkyl, or C 1-3 alkoxy,

[1563] R 17 is independently hydrogen, C 1-3 alkyl, or C 1-3 alkoxy,

[1564] R 18 is independently hydrogen, C 1-3 alkyl, or C 1-3 alkoxy,

[1565] and

[1566] R 19 is C 6-10- aryl,

[1567] wherein the C 6-10 aryl is a phenyl group substituted by one, two, or three substituents independently selected from: fluoride, chloride, and bromide.

[1568] In one embodiment of the present invention and / or its embodiments,

[1569] R 7Independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methylsulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl,

[1570] and

[1571] R 13 and R 14 together with the atom to which it is attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH- or -O-,

[1572] R 15 is independently hydrogen or C 1-3 alkoxy,

[1573] R 16 is independently hydrogen or C 1-3 alkoxy,

[1574] R 17 is independently hydrogen or C 1-3 alkoxy,

[1575] R 18 is independently hydrogen or C 1-3 alkoxy,

[1576] and

[1577] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl.

[1578] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iwi), (Iwii), (Iwiii), (Iwiv), (Iwv), (Iwvi), (Iwvii), (Iwviii), (Iwix), (Iwx), (Iwxi) or (Iwxii)

[1579]

[1580]

[1581]

[1582]

[1583] or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug, and mixtures thereof, wherein R 1 and R 25 are as defined in any of the embodiments described herein.

[1584] In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwi), preferably in the form of the (S)-enantiomer. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwii), preferably in the form of the (S)-enantiomer. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwiii), preferably in the form of the (S)-enantiomer. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwiv), preferably in the form of the (S)-enantiomer. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwv), preferably in the form of the (S)-enantiomer. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwvi), preferably in the form of the (S)-enantiomer. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwvii), preferably in the form of the (S)-enantiomer. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwviii), preferably in the form of the (S)-enantiomer. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwix), preferably in the form of the (S)-enantiomer. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwx), preferably in the form of the (S)-enantiomer. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwxi), preferably in the form of the (S)-enantiomer. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwixii), preferably in the form of the (S)-enantiomer.

[1585] In one embodiment of the invention and / or its embodiments,

[1586] R 7 is independently selected from

[1587] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 、C(=O)OR 10 、SR 10 、SOR10 、 SO 2 R 10 and C(=O)NR 11 R 12 ,

[1588] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, a 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally independently substituted with one or more substituents selected from

[1589] C 1-6- alkyl, C 3-10- cycloalkyl, a 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[1590] R 8 and R 9 are independently selected from

[1591] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, a 5- to 10-membered heterocyclic group and a 5- to 10-membered heteroaryl or

[1592] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1593] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, a 5- to 10-membered heterocyclic group or a 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally independently substituted with one or more substituents selected from

[1594] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” , C(=O)OR 10” and C(=O)NR 11” R 12” ,

[1595] R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[1596] R 8’ , R 9’ , R 10’ , R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[1597] R 8” , R 9” , R 10” , R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl,

[1598] and

[1599] R 13 and R 14 Together with the atoms to which they are attached, they form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally replaced by one or more C 1-3- alkyl, and / or one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[1600] R 15 are independently hydrogen, halogen, C 1-3 Alkyl, C 1-3 Alkoxy or NR 15’ R 15” , where R 15’ and R 15” Independently C 1-3- alkyl,

[1601] R 16 are independently hydrogen, halogen, C 1-3 Alkyl, C 1-3 Alkoxy or NR 16’ R 16” , where R 16’ and R 16” Independently C 1-3- alkyl,

[1602] R 17 are independently hydrogen, C 1-3 Alkyl or C 1-3 Alkoxy,

[1603] R 18 are independently hydrogen, C 1-3alkyl or C 1-3 alkoxy,

[1604] and

[1605] R 19 is independently selected from

[1606] C 6-10- aryl and 5- to 10-membered heteroaryl,

[1607] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted with one or more substituents independently selected from

[1608] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(=O)OR 22 and C(=O)NR 23 R 24 ,

[1609] R 20 and R 21 are independently selected from

[1610] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[1611] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 of the other ring atoms are selected from N, S and O,

[1612] wherein the C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is each optionally substituted with one or more substituents independently selected from

[1613] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR22’ and C(=O)NR 23’ R 24’ ,

[1614] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[1615] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl.

[1616] In one embodiment of the present invention and / or its embodiments,

[1617] R 7 Independently selected from

[1618] Hydrogen, C 1-6- Alkyl, C 2-6- alkenyl, 4 to 10 membered heterocyclic group, C 1-3- Alkoxy, hydroxyl, NR 8 R 9 ,

[1619] Among them C 1-6- Alkyl, C 2-6- alkenyl, 4 to 10 membered heterocyclic group or C 1-3- The alkoxy groups are each optionally substituted with one or more substituents independently selected from the following

[1620] C 1-3- Alkyl, 5- to 10-membered heterocyclic group, C 1-6- Alkoxy, halogen, cyano, hydroxyl, NR 8’ R 9’ ,

[1621] R 8 and R 9 Independently selected from

[1622] Hydrogen, C 1-6- Alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[1623] R 8 and R 9 together with the N atom to which it is attached, forms a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1624] Among them C 1-6- Alkyl, C6-10- An aryl or 5- to 10-membered heteroaryl or a heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the following

[1625] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ,

[1626] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1627] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1628] and

[1629] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, where one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[1630] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1631] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1632] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1633] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1634] and

[1635] R 19 is C 6-10- aryl,

[1636] wherein C 6-10An aryl is a phenyl group substituted by one, two or three substituents independently selected from fluoride, chloride and bromide.

[1637] In one embodiment of the present invention and / or its embodiments,

[1638] R 7 is independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methanesulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl,

[1639] and

[1640] R 13 and R 14 together with the atom to which it is attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N- or -S-,

[1641] R 15 is independently hydrogen or C 1-3 alkoxy,

[1642] R 16 is independently hydrogen or C 1-3 alkoxy,

[1643] R 17 is independently hydrogen or C 1-3 alkoxy,

[1644] R 18 is independently hydrogen or C 1-3 alkoxy.

[1645] and

[1646] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl.

[1647] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iwxiii), (Iwxiv), (Iwxv), (Iwxvi), (Iwxvii), (Iwxviii), (Iwxix) or (Iwxx)

[1648]

[1649]

[1650]

[1651] or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug, or mixture thereof, wherein R 1 and R 25 are as defined in any of the embodiments described herein.

[1652] In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwxiii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwxiv), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwxv), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwxvi), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwxvii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwxviii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwxix), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Iwxx), preferably in the (S)-enantiomeric form.

[1653] The invention provides a compound according to the invention and / or its embodiments, wherein R 7 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 and R 25 are as defined above.

[1654] In one embodiment of the invention and / or its embodiments,

[1655] R 7 is independently selected from

[1656] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R9 , C(=O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(=O)NR 11 R 12 ,

[1657] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally substituted independently by one or more substituents selected from

[1658] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[1659] R 8 and R 9 are independently selected from

[1660] hydrogen, C1 C1-6-alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group and 5- to 10-membered heteroaryl or

[1661] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1662] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted independently by one or more substituents selected from

[1663] C 1-6- alkyl, C1-6-alkoxy, halogen, cyano, hydroxy, NR 8” R 9” , C(=O)OR 10”and C(=O)NR 11” R 12” ,

[1664] R 10 、R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[1665] R 8’ 、R 9’ 、R 10’ 、R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[1666] R 8” 、R 9” 、R 10” 、R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl,

[1667] and

[1668] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the non-aromatic ring is optionally substituted by one or more C 1-3- alkyl or =O, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, -S(O)-, -S(O) 2 - or -S-,

[1669] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” wherein R 15’ and R 15” are independently C 1-3- alkyl,

[1670] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’ and R 16” are independently C 1-3- alkyl,

[1671] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1672] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1673] and

[1674] R 25 is hydrogen or methyl, preferably hydrogen.

[1675] In one embodiment of the present invention and / or its embodiments,

[1676] R 7 is independently selected from

[1677] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, a 4- to 10-membered heterocyclic group, C 1-3- alkoxy, hydroxy, NR 8 R 9 ,

[1678] wherein the C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group or C 1-3- alkoxy is each optionally substituted with one or more substituents independently selected from the following

[1679] C 1-3- alkyl, a 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ ,

[1680] R 8 and R 9 are independently selected from

[1681] hydrogen, C 1-6- alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[1682] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1683] wherein the C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the following

[1684] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ;

[1685] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1686] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1687] and

[1688] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, where one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O- or -S-,

[1689] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1690] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1691] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1692] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1693] and

[1694] R 25 is hydrogen or methyl, preferably hydrogen.

[1695] In one embodiment of the present invention and / or its embodiments,

[1696] R 7independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methylsulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl, and 3,3-difluoroazetidinyl,

[1697] and

[1698] R 13 and R 14 together with the atom to which it is attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH- or -O-,

[1699] R 15 is independently hydrogen or C 1-3 alkoxy,

[1700] R 16 is independently hydrogen or C 1-3 alkoxy,

[1701] R 17 is independently hydrogen or C 1-3 alkoxy,

[1702] R 18 is independently hydrogen or C 1-3 alkoxy, and

[1703] R 25 is hydrogen or methyl, preferably hydrogen.

[1704] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ixi), (Ixii), (Ixiii), (Ixiv), (Ixv) or (Ixvi)

[1705]

[1706]

[1707] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 1 and R 19 are defined as in any of the embodiments described herein.

[1708] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ixi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ixii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ixiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ixiv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ixv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ixvi), preferably in the (S)-enantiomeric form.

[1709] In one embodiment of the present invention and / or its embodiments,

[1710] R 7 is independently selected from

[1711] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, a 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 , C(=O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(=O)NR 11 R 12 ,

[1712] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, a 4- to 10-membered heterocyclic group or C 1-6- alkoxy is each optionally substituted by one or more substituents independently selected from the following

[1713] C 1-6- alkyl, C 3-10- cycloalkyl, a 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[1714] R8 and R 9 are independently selected from

[1715] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, and 5- to 10-membered heteroaryl; or

[1716] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O,

[1717] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, or 5- to 10-membered heteroaryl; or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from

[1718] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” 、C(=O)OR 10” and C(=O)NR 11” R 12” ,

[1719] R 10 、R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[1720] R 8’ 、R 9’ 、R 10’ 、R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[1721] R 8” 、R 9” 、R 10” 、R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl,

[1722] and

[1723] R 13 and R 14Together with the atom to which it is attached, form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally substituted by one or more C 1-3- alkyl groups, and / or wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[1724] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” , wherein R 15’ and R 15” are independently C 1-3- alkyl,

[1725] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” , wherein R 16’ and R 16” are independently C 1-3- alkyl,

[1726] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1727] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1728] and

[1729] R 25 is hydrogen or methyl, preferably hydrogen.

[1730] In one embodiment of the present invention and / or its embodiments,

[1731] R 7 is independently selected from

[1732] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group, C 1-3- alkoxy, hydroxy, NR 8 R 9 ,

[1733] wherein C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group or C 1-3- alkoxy is each optionally substituted by one or more substituents independently selected from the following

[1734] C 1-3- alkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ ,

[1735] R 8 and R 9 are independently selected from

[1736] hydrogen, C 1-6- alkyl, C 6-10- aryl and 5- to 10-membered heteroaryl or

[1737] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1738] wherein C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the following

[1739] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ;

[1740] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1741] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1742] and

[1743] R 13 and R 14 together with the atoms to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[1744] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3Alkoxy

[1745] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1746] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1747] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1748] And

[1749] R 25 is hydrogen or methyl, preferably hydrogen

[1750] In one embodiment of the present invention and / or its embodiments

[1751] R 7 is independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, methanesulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl

[1752] And

[1753] R 13 and R 14 together with the atoms to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N- or -S-

[1754] R 15 is independently hydrogen or C 1-3 alkoxy

[1755] R 16 is independently hydrogen or C 1-3 alkoxy

[1756] R 17 is independently hydrogen or C 1-3 alkoxy

[1757] R 18 is independently hydrogen or C 1-3 alkoxy

[1758] And

[1759] R 25 is hydrogen or methyl, preferably hydrogen.

[1760] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Ixvii), (Ixviii), (Ixix) or (Ixx)

[1761]

[1762] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs and mixtures thereof, wherein R 1 and R 19 are defined as in any of the embodiments described herein.

[1763] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ixvii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ixviii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ixix), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Ixx), preferably in the (S)-enantiomeric form.

[1764] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 7 , R 19 and R 25 are as defined above.

[1765] In one embodiment of the present invention and / or its embodiments,

[1766] R 7 is independently selected from

[1767] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8 R 9 , C(=O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(=O)NR 11 R 12 ,

[1768] wherein C1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 4- to 10-membered heterocyclic group, or C 1-6- alkoxy is each optionally independently substituted with one or more substituents selected from the following

[1769] C 1-6- alkyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ , C(=O)OR 10’ and C(=O)NR 11’ R 12’ ,

[1770] R 8 and R 9 are independently selected from

[1771] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, and 5- to 10-membered heteroaryl, or

[1772] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2, or 3 other ring atoms are selected from N, S, and O,

[1773] wherein C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heterocyclic group, or 5- to 10-membered heteroaryl, or the heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is optionally independently substituted with one or more substituents selected from the following

[1774] C 1-6- alkyl, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8” R 9” , C(=O)OR 10” and C(=O)NR 11” R 12” ,

[1775] R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[1776] R 8’ , R 9’ , R 10’ , R 11’ and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[1777] R 8” , R 9” , R 10” , R 11” and R 12” are independently selected from hydrogen and C 1-6- alkyl,

[1778] and

[1779] R 19 Independently selected from

[1780] C 6-10- aryl and 5- to 10-membered heteroaryl,

[1781] Among them C 6-10- The aryl or 5- to 10-membered heteroaryl groups are each optionally substituted with one or more substituents independently selected from the following

[1782] C 1-6- Alkyl, C 3-10- Cycloalkyl, C 1-6- Alkoxy, 5- to 10-membered heterocyclic group, C 6-10- Aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 、C(=O)OR 22 and C(=O)NR 23 R 24 ,

[1783] R 20 and R 21 Independently selected from

[1784] Hydrogen, C 1-6- Alkyl, C 3-10- Cycloalkyl and C 6-10- Aryl or

[1785] R 20 and R 21 together with the N atom to which it is attached, forms a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1786] Among them C 1-6- Alkyl, C 3-10- Cycloalkyl or C 6-10- Aryl or R 20 and R 21The heterocycles formed together with the N atoms to which they are attached are each optionally substituted by one or more substituents independently selected from the following

[1787] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’ ,

[1788] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[1789] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl,

[1790] and

[1791] R 25 is hydrogen or methyl, preferably hydrogen.

[1792] In one embodiment of the present invention and / or its embodiments, R 7 is independently selected from hydrogen, C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group, C 1-3- alkoxy, hydroxy, NR 8 R 9 ,

[1793] wherein C 1-6- alkyl, C 2-6- alkenyl, 4- to 10-membered heterocyclic group or C 1-3- alkoxy is each optionally substituted by one or more substituents independently selected from the following

[1794] C 1-3- alkyl, 5- to 10-membered heterocyclic group, C 1-6- alkoxy, halogen, cyano, hydroxy, NR 8’ R 9’ ,

[1795] R 8 and R 9 are independently selected from

[1796] Hydrogen, C 1-6- Alkyl, C 6-10- Aryl and 5- to 10-membered heteroaryl or

[1797] R 8 and R 9 together with the N atom to which it is attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein one ring atom is N and wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O;

[1798] wherein C 1-6- alkyl, C 6-10- aryl or 5- to 10-membered heteroaryl or the heterocycle formed by R 8 and R 9 together with the N atom to which it is attached is optionally substituted by one or more substituents independently selected from the following

[1799] C 1-6- alkyl, C 1-6- alkoxy, hydroxy and NR 8” R 9” ;

[1800] R 8’ and R 9’ are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1801] R 8” and R 9” are independently selected from hydrogen or C 1-3- alkyl, preferably selected from hydrogen, methyl or ethyl,

[1802] and

[1803] R 19 is C 6-10- aryl,

[1804] wherein C 6-10 aryl is phenyl substituted by one, two or three substituents independently selected from: fluoride, chloride and bromide,

[1805] and

[1806] R 25 is hydrogen or methyl, preferably hydrogen.

[1807] In one embodiment of the present invention and / or its embodiments,

[1808] R 7independently selected from methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylthio, ethylthio, methylsulfinyl, mesyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxyethylamino, methoxyethylamino, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 3-fluoroazetidinyl, and 3,3-difluoroazetidinyl,

[1809] and

[1810] R 19 independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl, and 3,5-dichlorophenyl,

[1811] and

[1812] R 25 is hydrogen or methyl, preferably hydrogen.

[1813] In one embodiment of the present invention and / or its embodiments, the compound is represented by formula (Iyi), (Iyii), (Iyiii), (Iyiv), (Iyv) or (Iyvi)

[1814]

[1815]

[1816] or its stereoisomers, physiologically acceptable salts, esters, solvates, polymorphs, prodrugs, and mixtures thereof, wherein R 1 、R 13 、R 14 、R 15 、R 16 、R 17 and R 18 are defined as in any of the embodiments described herein.

[1817] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iyi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iyii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iyiii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iyiv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iyv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iyvi), preferably in the (S)-enantiomeric form.

[1818] The present invention provides a compound according to the present invention and / or its embodiments, wherein R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 25 are as defined above.

[1819] In one embodiment of the present invention and / or its embodiments,

[1820] R 13 and R 14 together with the atoms to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein the non-aromatic ring is optionally substituted by one or more C 1-3- alkyl or =O, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O-, -S(O)-, -S(O) 2 - or -S-,

[1821] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” , wherein R 15’ and R 15” are independently C 1-3- alkyl,

[1822] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” , wherein R 16’and R 16” is independently C 1-3- alkyl

[1823] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1824] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

[1825] and

[1826] R 19 is independently selected from

[1827] C 6-10- aryl and 5- to 10-membered heteroaryl

[1828] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted with one or more substituents independently selected from

[1829] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 、C(=O)OR 22 and C(=O)NR 23 R 24 ,

[1830] R 20 and R 21 are independently selected from

[1831] hydrogen, C 1-6- alkyl, C3-10-cycloalkyl and C6-10-aryl or

[1832] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1833] wherein the C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or the heterocycle formed by R 20 and R 21 together with the N atom to which they are attached is each optionally substituted with one or more substituents independently selected from the following

[1834] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’ ,

[1835] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[1836] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl,

[1837] and

[1838] R 25 is hydrogen or methyl, preferably hydrogen.

[1839] In one embodiment of the present invention and / or its embodiments,

[1840] R 13 and R 14 together with the atoms to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -O- or -S-,

[1841] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1842] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1843] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1844] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1845] and

[1846] R 19 is C 6-10- aryl,

[1847] wherein C 6-10 aryl is phenyl substituted by one, two or three substituents independently selected from: fluoride, chloride and bromide,

[1848] and

[1849] R 25 is hydrogen or methyl, preferably hydrogen.

[1850] In one embodiment of the present invention and / or its embodiments,

[1851] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH- or -O-,

[1852] R 15 is independently hydrogen or C 1-3 alkoxy,

[1853] R 16 is independently hydrogen or C 1-3 alkoxy,

[1854] R 17 is independently hydrogen or C 1-3 alkoxy,

[1855] R 18 is independently hydrogen or C 1-3 alkoxy,

[1856] and

[1857] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl,

[1858] and

[1859] R 25 is hydrogen or methyl, preferably hydrogen.

[1860] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Izi), (Izii), (Iziii), (Iziv), (Izv) or (Izvi)

[1861]

[1862]

[1863]

[1864] or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug thereof, and mixtures thereof, wherein R 1 and R 7 are as defined in any one of the embodiments described herein.

[1865] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Izi), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Izii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iziii), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Iziv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Izv), preferably in the (S)-enantiomeric form. In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Izvi), preferably in the (S)-enantiomeric form.

[1866] In one embodiment of the present invention and / or its embodiments,

[1867] R 13 and R 14 together with the atoms to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein the aromatic ring is optionally substituted by one or more C 1-3- alkyl groups, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[1868] R 15 independently is hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” wherein R 15’ and R 15” independently are C 1-3- alkyl,

[1869] R 16 independently is hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” wherein R 16’and R 16” is independently C 1-3- alkyl,

[1870] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1871] R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1872] and

[1873] R 19 is independently selected from

[1874] C 6-10- aryl and 5- to 10-membered heteroaryl,

[1875] wherein each C 6-10- aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more substituents independently selected from the following

[1876] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(=O)OR 22 and C(=O)NR 23 R 24 ,

[1877] R 20 and R 21 are independently selected from

[1878] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl and C 6-10- aryl or

[1879] R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1880] wherein C 1-6- alkyl, C 3-10- cycloalkyl or C 6-10- aryl or formed by R 20 and R 21The heterocycles formed together with the N atoms to which they are attached are each optionally substituted by one or more substituents independently selected from the following

[1881] C 1-6- alkyl, C 3-10- cycloalkyl, C 1-6- alkoxy, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, halogen, cyano, hydroxy, NR 20’ R 21’ , C(=O)OR 22’ and C(=O)NR 23’ R 24’ ,

[1882] R 22 、R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[1883] R 20’ 、R 21’ 、R 22’ 、R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl,

[1884] and

[1885] R 25 is hydrogen or methyl, preferably hydrogen.

[1886] In one embodiment of the present invention and / or its embodiments,

[1887] R 13 and R 14 together with the atoms to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, where one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[1888] R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1889] R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1890] R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1891] R 18Independently is hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

[1892] and

[1893] R 19 is C 6-10- aryl,

[1894] wherein the C 6-10 aryl is a phenyl group substituted with one, two or three substituents independently selected from: fluoride, chloride and bromide,

[1895] and

[1896] R 25 is hydrogen or methyl, preferably hydrogen.

[1897] In one embodiment of the present invention and / or its embodiments,

[1898] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N- or -S-,

[1899] R 15 independently is hydrogen or C 1-3 alkoxy,

[1900] R 16 independently is hydrogen or C 1-3 alkoxy,

[1901] R 17 independently is hydrogen or C 1-3 alkoxy,

[1902] R 18 independently is hydrogen or C 1-3 alkoxy.

[1903] and

[1904] R 19 is independently selected from 2,3-difluorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl and 3,5-dichlorophenyl,

[1905] and

[1906] R 25 is hydrogen or methyl, preferably hydrogen.

[1907] In one embodiment of the present invention and / or its embodiments, the compound is according to formula (Izvii), (Izviii), (Izix) or (Izx)

[1908]

[1909] or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug thereof, and mixtures thereof, wherein R 1 and R 7 is as defined in any of the embodiments described herein.

[1910] In one embodiment of the invention and / or its embodiments, the compound is according to formula (Izvii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Izviii), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound is according to formula (Izix), preferably in the (S)-enantiomeric form. In one embodiment of the invention and / or its embodiments, the compound according to formula (Izx) is preferably in the (S)-enantiomeric form.

[1911] The compounds according to the invention can be considered an "active" agent, which is herein considered a substance capable of inhibiting worms such as Dirofilaria, especially Dirofilaria immitis. The term "inhibiting growth" refers to a decrease in the growth rate of the worm population. Thus, the term includes cases where the number of worms increases but at a reduced rate, cases where the inhibition of population growth stops, and cases where the number of worms in the population decreases or even disappears.

[1912] Furthermore, the present invention provides a method for preparing a compound according to formula (I), comprising the steps

[1913] reacting a compound of formula (A)

[1914]

[1915] with a compound of formula (B)

[1916] Hal-R 19

[1917] Formula (B)

[1918] wherein

[1919] Hal is a halogen

[1920] R 1 is independently selected from

[1921] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10Aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, C 1-6- alkylthio, halogen, cyano, nitro, hydroxy, mercapto, NR 2 R 3 , COOH, C(=O)OR 4 , SR 4 , SOR 4 , SO 2 R 4 , SO 2 NR 5 R 6 and C(=O)NR 5 R 6 ,

[1922] wherein C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10 aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy or C 1-6- alkylthio is each optionally independently substituted with one or more substituents selected from the following

[1923] C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, C 1-6- alkylthio, halogen, cyano, nitro, hydroxy, mercapto, NR 2’ R 3’ , C(=O)OR 4’ , SR 4’ , SOR 4’ , SO 2 R 4’ , SO 2 NR 5’ R 6’ and C(=O)NR 5’ R 6’ ,

[1924] R 2 and R 3 are independently selected from

[1925] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy-C 1-6- alkyl, C 3-10- alkyl substituted with cycloalkyl 1-6- alkyl, C 1-6- alkyl substituted with 5- to 10-membered heterocyclic group 6-10- alkyl, C 1-6- alkyl substituted with aryl and C 1-6- alkyl substituted with 5- to 10-membered heteroaryl, or

[1926] R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1927] wherein C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy-C 1-6- alkyl, C 3-10- alkyl substituted with cycloalkyl 1-6- alkyl, C 1-6- alkyl substituted with 5- to 10-membered heterocyclic group 6-10- alkyl, C 1-6- alkyl substituted with aryl or C 1-6- alkyl substituted with 5- to 10-membered heteroaryl or formed by R 2 and R 3 each of the heterocycles formed together with the N atom to which they are attached is optionally substituted independently with one or more substituents selected from the following

[1928] C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 2” R 3” 、C(=O)OR 4” 、SR 4” 、SOR 4 、SO 2 R 4” 、SO 2 NR 5” R 6”and C(=O)NR 5” R 6” ,

[1929] R 4 , R 5 and R 6 are independently selected from hydrogen and C 1-6- alkyl,

[1930] R 2’ , R 3’ , R 4’ , R 5’ and R 6’ are independently selected from hydrogen and C 1-6- alkyl,

[1931] R 2” , R 3” , R 4” , R 5” and R 6” are independently selected from hydrogen and C 1-6- alkyl,

[1932] R 7 Independently selected from

[1933] Hydrogen, C 1-6- Alkyl, C 2-6- Alkenyl, C 2-6- Alkynyl, C 3-10- Cycloalkyl, 4- to 10-membered heterocyclic group, C 6-10 Aryl, 5- to 10-membered heteroaryl, C 1-6- Alkoxy, C 1-6- Alkylthiol, halogen, cyano, nitro, hydroxyl, mercapto, NR 8 R 9 、COOH、C(=O)OR 10 , SR 10 , SOR 10 、SO 2 R 10 、SO 2 NR 11 R 12 and C(=O)NR 11 R 12 ,

[1934] Among them C 1-6- Alkyl, C 2-6- Alkenyl, C 2-6- Alkynyl, C 3-10- Cycloalkyl, 4- to 10-membered heterocyclic group, C 6-10 Aryl, 5- to 10-membered heteroaryl, C 1-6- Alkoxy or C 1-6- Each alkylthiol group is optionally substituted with one or more substituents independently selected from the following

[1935] C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, C 1-6- alkylthio, halogen, cyano, nitro, hydroxy, mercapto, NR 8’ R 9’ , C(=O)OR 10’ , SR 10’ , SOR 10’ , SO 2 R 10’ , SO 2 NR 11’ R 12’ and C(=O)NR 11’ R 12’ ,

[1936] R 8 and R 9 are independently selected from

[1937] hydrogen, C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy-C 1-6- alkyl, C 3-10- alkyl substituted with C 1-6- cycloalkyl, C 1-6- alkyl substituted with a 5- to 10-membered heterocyclic group, C 6-10- alkyl substituted with C 1-6- aryl, C 1-6- alkyl substituted with a 5- to 10-membered heteroaryl, or

[1938] R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O, wherein C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy-C 1-6- alkyl, C 3-10-Cycloalkyl-substituted C 1-6- alkyl, C 1-6- alkyl substituted by a 5- to 10-membered heterocyclic group, C 6-10- alkyl substituted by an aryl, C 1-6- alkyl, or C 1-6- alkyl substituted by a 5- to 10-membered heteroaryl, or a heterocycle formed by R 8 and R 9 together with the N atom to which they are attached is each optionally substituted by one or more substituents independently selected from the following

[1939] C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 8” R 9” , C(=O)OR 10” , SR 10” , SOR 10” , SO 2 R 10” , SO 2 NR 11” R 12” and C(=O)NR 11” R 12” ,

[1940] R 10 , R 11 , and R 12 are independently selected from hydrogen and C 1-6- alkyl,

[1941] R 8’ , R 9’ , R 10’ , R 11’ , and R 12’ are independently selected from hydrogen and C 1-6- alkyl,

[1942] R 8” , R 9” , R 10” , R 11” , and R 12” are independently selected from hydrogen and C 1-6- alkyl,

[1943] R 13 is hydrogen or C 1-3 alkyl,

[1944] R 14 is hydrogen, C1-3 alkyl, C 1-3 alkoxy, NR 14’ R 14” , where R 14’ and R 14” are independently C 1-3- alkyl or

[1945] R 13 and R 14 together with the atom to which they are attached form a non-aromatic ring containing 5 or 6 carbon atoms, where the ring containing 5 or 6 carbon atoms is optionally substituted by one or more C 1-3 -alkyl or =O, and / or where one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O-, -S(O)-, -S(O) 2 - or -S-, or

[1946] R 13 and R 14 together with the atom to which they are attached form an aromatic ring containing 5 or 6 carbon atoms, where the ring containing 5 or 6 carbon atoms is optionally substituted by one or more C 1-3 -alkyl, and / or where one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-,

[1947] R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15’ R 15” , where R 15’ and R 15” are independently C 1-3- alkyl,

[1948] R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16’ R 16” , where R 16’ and R 16” are independently C 1-3- alkyl,

[1949] R 17 is independently hydrogen, C 1-3 alkyl, C 1-3 alkoxy or NR 17’ R 17” , where R 17’ and R 17” are independently C 1-3- alkyl,

[1950] R 18 is independently hydrogen, C 1-3 alkyl, C 1-3 alkoxy or NR 18’ R 18” , where R 18’ and R 18” are independently C 1-3- alkyl,

[1951] R 19 is independently selected from the following C 6-10- aryl and 5- to 10-membered heteroaryl,

[1952] wherein the C 6-10- aryl or 5- to 10-membered heteroaryl is each optionally substituted with one or more substituents independently selected from the following

[1953] C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy, C 1-6- alkylthio, halogen, cyano, nitro, hydroxy, mercapto, NR 20 R 21 , C(=O)OR 22 , SR 22 , SOR 22 , SO 2 R 22 , SO 2 , NR 23 R 24 and C(=O)NR 23 R 24 ,

[1954] R 20 and R 21 are independently selected from

[1955] hydrogen, C 1-6- alkyl, C 3-10- cycloalkyl, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy-C 1-6- alkyl, C 6-10- alkyl substituted with C 1-C6- aryl, C 1-6- alkyl substituted with 5- to 10-membered heteroaryl, or

[1956] R 20 and R 21Together with the N atom to which it is attached, form a saturated or unsaturated heterocycle having 3 to 12 ring atoms, wherein 0, 1, 2 or 3 other ring atoms are selected from N, S and O,

[1957] wherein C 1-6- alkyl, C 2-6- alkenyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C 1-6- alkoxy or C1-6-alkylthio or a heterocycle formed by R 20 and R 21 Together with the N atom to which it is attached, each of the heterocycles is optionally substituted by one or more substituents independently selected from the following

[1958] C 1-6- alkyl, C 2-6- alkenyl, C 2-6- alkynyl, C 3-10- cycloalkyl, 5- to 10-membered heterocyclic group, C 6-10- aryl, 5- to 10-membered heteroaryl, C1-6-alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 20’ R 21’ , C(=O)OR 22’ , SR 22’ , SOR 22’ , SO 2 R 22’ , SO 2 , NR 23’ R 24’ and C(=O)NR 23’ R 24’

[1959] R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6- alkyl,

[1960] R 20’ , R 21’ , R 22’ , R 23’ and R 24’ are independently selected from hydrogen and C 1-6- alkyl,

[1961] R 25 is independently selected from hydrogen and C 1-6- alkyl

[1962] to obtain a compound according to formula (I).

[1963] In one embodiment of the present invention and / or its embodiments, with respect to R 1 , R7 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 25 This also applies to the above description of the compounds of the present invention.

[1964] In one embodiment of the present invention and / or its embodiments, Hal is a halogen selected from the following: chloride, bromide or iodide, preferably bromide or iodide, particularly iodide.

[1965] The compounds of formula (A) and formula (B) are commercially available or can be synthesized.

[1966] In one embodiment of the present invention and / or its embodiments, the compound of formula (A) can be referred to as a compound containing an azaindole structure, wherein the 7-position of the azaindole is not substituted by the compound of formula (B), and it can form a compound containing an azaindole structure, wherein the 7-position corresponding to the 7-position of the azaindole is substituted by the residue R in an organic solvent in the presence of a coupling agent. 1 substituted.

[1967] Examples of coupling agents include but are not limited to copper(I) salts such as CuCl, Cu 2 O, Cu(I), or copper(II) salts such as CuO, Cu(OAc) 2 , preferably Cu(I).

[1968] In one embodiment of the present invention and / or its embodiments, the method can be carried out in the presence of oxygen.

[1969] Organic solvents are known to those skilled in the art.

[1970] Suitable organic solvents for the method according to the present invention can be, for example, acetonitrile, dioxane, tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), N-methyl-2-pyrrolidone (NMP), preferably dimethylacetamide (DMA) or N-methyl-2-pyrrolidone (NMP), particularly (DMA).

[1971] In one embodiment of the present invention and / or its embodiments, the method can be carried out in the presence of an auxiliary basic compound.

[1972] Suitable basic compounds may include organic compounds, including but not limited to pyridines such as 4-(dimethylamino)pyridine (DMAP), amidines such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), and amines such as triethylamine and diisopropylethylamine, diamino compounds such as 1,2-dimethylethylenediamine, N,N'-dimethylcyclohexane-1,2-diamine, preferably 1,2-dimethylethylenediamine, N,N'-dimethylcyclohexane-1,2-diamine.

[1973] Suitable basic compounds may include inorganic compounds, including but not limited to carbonates such as sodium carbonate, potassium carbonate or cesium carbonate, or hydroxides such as sodium hydroxide, preferably carbonates, especially potassium carbonate.

[1974] In one embodiment of the present invention and / or its embodiments, the method may be carried out at an elevated temperature. The elevated temperature ranges from 23 °C (room temperature) to the boiling temperature of the organic solvent. This means that in the case of using dimethylacetamide with a boiling temperature or boiling point of 165 °C as the organic solvent, the method may preferably be carried out at 23 °C to 165 °C. All temperatures referred to herein and related to the boiling temperature or boiling point are temperatures measured at an atmospheric pressure of 101 kPa.

[1975] In one embodiment of the present invention and / or its embodiments, the method may be carried out in a sealed container. In the case where the method is carried out in a sealed container, the reaction mixture may be heated to a temperature higher than the boiling point of the solvent, but preferably not higher than 25 °C above the boiling point of the solvent.

[1976] In one embodiment of the present invention and / or its embodiments, the method may preferably be carried out with mechanical movement, such as stirring and / or microwave treatment.

[1977] Furthermore, the present invention provides a veterinary pharmaceutical composition comprising a compound according to the present invention and one or more physiologically acceptable excipients.

[1978] The veterinary pharmaceutical composition of the present invention and / or its embodiments comprises a therapeutically effective amount of the compound of the present invention and / or its embodiments, formulated together with one or more physiologically acceptable excipients.

[1979] Physiologically acceptable excipients are known in the art. For example, they are described in "Gennaro, Remington: The Science and Practice of Pharmacy" (20th Edition, 2000). All these physiologically acceptable excipients must be substantially pharmaceutically or veterinarily pure and non-toxic in the amounts used and must be compatible with the active ingredient.

[1980] In a preferred embodiment of the present invention and / or its embodiments, one or more physiologically acceptable excipients are selected from carriers, binders, antioxidants, buffers, sugar components, surfactants, lubricants, stabilizers, glidants, disintegrants, and preservatives and mixtures thereof.

[1981] As used herein, the term "carrier" refers to any type of non-toxic, inert, solid, semi-solid or liquid filler or diluent that carries / encapsulates any type of material. Some examples of materials that can be used as physiologically acceptable carriers are, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; esters such as ethyl oleate and ethyl laurate; agar.

[1982] A binder is a substance that can cause other substances to stick together. A binder is (in the case where the binder is a polymer) preferably a component having a melting temperature or glass transition temperature (T g ) in the range of 25 to 100 °C, preferably 35 to 85 °C, particularly 40 to 70 °C. The glass transition temperature is the temperature at which a polymer becomes brittle upon cooling and softens upon heating. This means that a hydrophilic polymer will soften at a temperature above the glass transition temperature (T g ) and can be plastically deformed without breaking. The glass transition temperature or melting point is determined by methods known to those skilled in the art.

[1983] In a preferred embodiment of the present invention and / or its embodiments, the binder is selected from polyethylene glycol, polypropylene glycol, polyethylene glycol - polypropylene glycol copolymer, microcrystalline wax, glycerol monostearate, hydrogenated castor oil, polyethylene glycol hydroxystearate glycerol ester, polysaccharides, polyvinylpyrrolidone, polyvinyl alcohol, poly(meth)acrylate, polyvinylpyrrolidone - polyacetate copolymer, and mixtures thereof.

[1984] An antioxidant is a substance used to inhibit oxidation. Antioxidants suitable for inclusion in the soft chew veterinary dosage form of the present invention include, but are not limited to, ascorbic acid, glutathione, tocopherols and their esters, tert-butylhydroquinone (TBHQ), butylated hydroxyanisole (BHA also known as 2-tert-butyl-4-hydroxyanisole, 3-tert-butyl-4-hydroxyanisole or a mixture thereof), and butylated hydroxytoluene (BHT also known as 2,6-di-tert-butyl-4-methylphenol). Preferably, the antioxidant is present in an aggregate. In a preferred embodiment of the present invention and / or its embodiments, the antioxidant included in the veterinary preparation can be in the range of 0.001 to 1.00% by weight.

[1985] Buffers are substances that maintain / regulate the pH value of the product. Non-limiting examples of buffers are bicarbonates, dihydrogen phosphates, and hydrogen phosphates.

[1986] The sugar component is used to sweeten the taste of the product. It includes natural sugars (carbohydrates) and sugar substitutes. In a preferred embodiment of the present invention and / or its embodiments, the buffer contained in the veterinary pharmaceutical preparation may be in the range of 1 to 10% by weight.

[1987] Surfactants can be regarded as substances that reduce the interfacial tension between two phases. Common surfactants are alkyl sulfates (such as sodium lauryl sulfate), alkyltrimethylammonium salts, alcohol ethoxylates, etc. In a preferred embodiment of the present invention and / or its embodiments, the surfactant contained in the veterinary pharmaceutical preparation may be in the range of 0.1 to 10.0% by weight.

[1988] Lubricants are generally considered to be substances suitable for reducing friction such as static friction, sliding friction, and rolling friction. The lubricant is preferably a stearate or a fatty acid, more preferably an alkaline earth metal stearate such as magnesium stearate. In a preferred embodiment of the present invention and / or its embodiments, the lubricant contained in the veterinary pharmaceutical preparation may be in the range of 0.1 to 10.0% by weight.

[1989] Stabilizers are physiologically acceptable excipients that help preserve the product. Examples include but are not limited to alginates, carrageenans, gelatin, pectin, and natural gums. In a preferred embodiment of the present invention and / or its embodiments, the surfactant contained in the veterinary pharmaceutical preparation may be in the range of 0.01 to 3.0% by weight.

[1990] Glidants, also known as flow aids, can be used to improve fluidity. Traditionally, talc has been used as a flow aid, but now it has been almost completely replaced by colloidal silica. In a preferred embodiment of the present invention and / or its embodiments, the glidant contained in the veterinary pharmaceutical preparation may be in the range of 1 to 3% by weight.

[1991] A disintegration agent, also known as a disintegrant, is a compound that enhances the ability of a dosage form, preferably a tablet, to break into smaller fragments when in contact with a liquid, preferably water. Non-limiting examples of disintegration agents include sodium carboxymethyl starch, sodium starch glycolate, cross-linked polyvinylpyrrolidone, sodium carboxymethyl glycolate, preferably sodium starch glycolate. In a preferred embodiment of the present invention and / or its embodiments, the surfactant contained in the veterinary pharmaceutical preparation may be in the range of 1.0 to 7.0% by weight.

[1992] Preservatives are substances that can be added to prevent the growth of microorganisms or decomposition by adverse chemical changes. Non-limiting examples include lactic acid, benzoic acid benzoates, and parabens. In a preferred embodiment of the present invention and / or its embodiments, the surfactant included in the veterinary pharmaceutical preparation can be in the range of 0.01 to 1.0% by weight.

[1993] The compounds according to the present invention can be administered in a variety of dosage forms. The term "dosage form" refers to a product in which the compound according to the present invention is formulated to be suitable for administration to an animal by the contemplated route of administration. Such dosage forms are sometimes referred to herein as pharmaceutical preparations or pharmaceutical compositions.

[1994] The pharmaceutical compositions of the present invention and / or their embodiments can be administered to animals orally, rectally, vaginally, parenterally, topically, orally, or nasally.

[1995] In a preferred embodiment of the present invention and / or its embodiments, the dosage form for oral administration can be a liquid or solid dosage form.

[1996] The liquid dosage forms of the compound are generally solutions, suspensions, or emulsions. A solution is a mixture of two or more components that forms a single phase that is uniform at the molecular level. A suspension consists of insoluble solid particles dispersed in a liquid medium, and the solid particles account for about 0.5% to about 30% of the suspension. The liquid can be aqueous, oily, or both. An emulsion is a heterogeneous dispersion of one immiscible liquid in another; it relies on an emulsifier for stabilization. Dry powder (or granules) for reconstitution is mixed with a diluent (e.g., water) and reconstituted into a solution or suspension immediately before injection. The main advantage of this dosage form is that it overcomes the problem of instability of solutions or suspensions.

[1997] Liquid formulations for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, extracts, feed or drinking water formulations, and elixirs. A gastric lavage fluid is a liquid oral formulation that is administered directly into the mouth / throat of an animal, especially a dog, using a "stomach tube gun" or syringe or other suitable device. When the composition is administered in the drinking water of the animal recipient or as an infusion, it may be convenient to use a solution or suspension formulation. For example, such a formulation can be a concentrated suspension mixed with water or a dry formulation mixed and suspended in water. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers, and emulsifying agents, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butanediol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, and fatty acid esters of sorbitol and mixtures thereof. In addition to the inert diluents, oral compositions may also contain adjuvants such as wetting agents, emulsifying agents, and suspending agents, sweetening agents, flavoring agents, and perfumes.

[1998] Solid dosage forms for oral administration include capsules, tablets, dragees, pills, powders, and granules, chewable snacks, premixes, and boluses. In such solid dosage forms, the active compound is admixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or calcium phosphate and / or a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; c) humectants, such as glycerol; d) disintegrating agents, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarders, such as paraffin; f) absorption promoters, such as quaternary ammonium compounds; g) wetting agents, such as cetyl alcohol and glycerol monostearate; h) absorbents, such as kaolin and bentonite; i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also contain buffering agents.

[1999] The active compound can also be in microencapsulated form with one or more excipients as described above. Solid dosage forms of tablets, dragees, capsules, pills, and granules c...

Claims

1. A compound of formula (I) wherein R 1 independently selected from: Hydrogen, C 1-6 -alkyl, wherein C 1-6 - the alkyl group is optionally substituted by one or more substituents independently selected from halogen, R 7 independently selected from: C 1-6 - alkyl, 4- to 10-membered heterocyclic group, C 1-6 - alkoxy, hydroxy, NR 8 R 9 , wherein C 1-6 -alkyl, 4- to 10-membered heterocyclic group, C 1-6 -alkoxy is each optionally substituted with one or more substituents independently selected from halogen R 8 and R 9 are independently selected from C 1-6 -alkyl, R 13 is hydrogen or C 1-3 alkyl, R 14 is hydrogen, C 1-3 alkyl, or R 13 and R 14 together with the atom(s) to which it is attached form a non-aromatic ring having 5 or 6 carbon atoms, wherein the ring having 5 or 6 carbon atoms is optionally substituted by one or more C 1-3 -alkyl or =O, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -O-, or R 13 and R 14 together with the atom to which it is attached form an aromatic ring containing 5 or 6 carbon atoms, wherein the ring containing 5 or 6 carbon atoms is optionally substituted by one or more C 1-3 -alkyl groups, and / or wherein one or more of the carbon atoms forming the ring are optionally replaced by -NH-, -N=, =N-, -O- or -S-, R 15 independently is hydrogen, R 16 independently is hydrogen, R 17 is independently hydrogen, R 18 independently is hydrogen, R 19 independently selected from C 6 aryl, wherein C 6 The aryl is optionally substituted by one or more substituents independently selected from: C 1-6 -alkyl, C 1-6 -alkoxy, halogen, NR 20 R 21 , R 20 and R 21 are independently selected from C 1-6 -alkyl, R 25 independently selected from hydrogen and C 1-6 -alkyl, or a stereoisomer, physiologically acceptable salt and mixture thereof.

2. The compound according to claim 1, wherein R 1 is independently selected from hydrogen, methyl, trifluoromethyl and ethyl.

3. The compound according to claim 1, wherein R 7 is independently selected from methyl, ethyl, isopropyl, methoxy, ethoxy, hydroxy, dimethylamino and morpholin-4-yl.

4. The compound according to claim 1, wherein R 19 is C 6 aryl, Wherein said C 6 aryl is a phenyl group substituted by one, two or three substituents independently selected from the following: F, Cl and Br.

5. The compound according to claim 1, wherein R 25 is hydrogen.

6. The compound according to claim 1, which exists in the form of the (S)-enantiomer.

7. A method for preparing a compound of formula (I) according to any one of claims 1 to 5, comprising the steps of reacting a compound of formula (A) with a compound of formula (B), Hal-R 19 formula (B) wherein Hal is a halogen and R 1 、R 7 、R 13 、R 14 、R 15 、R 16 、R 17 、R 18 、R 19 and R 25 as defined in any one of claims 1 to 5, to obtain a compound of formula (I).

8. A veterinary pharmaceutical composition comprising - a compound of formula (I) according to any one of claims 1 to 6, and - one or more physiologically acceptable excipients.

9. The veterinary pharmaceutical composition according to claim 8, wherein the one or more physiologically acceptable excipients are selected from carriers, fillers, flavoring agents, binders, antioxidants, buffering agents, sugar components, lubricants, surfactants, stabilizers, glidants, disintegrants and preservatives, and mixtures thereof.

10. Use of a compound of formula (I) according to any one of claims 1 to 6 or the veterinary pharmaceutical composition according to claim 8 or 9 in the preparation of a medicament for treating a disorder / disease caused by worms.

11. The use according to claim 10, wherein the disease is heartworm disease.

12. The use according to claim 10, wherein the worm is Dirofilaria immitis.

Images